Altered	O
memory	B-cell_type
T	I-cell_type
cell	I-cell_type
differentiation	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
.	O

The	O
chronic	O
immune	O
response	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
might	O
be	O
driven	O
by	O
activated	O
Th1	O
cells	O
without	O
sufficient	O
Th2	O
cell	O
differentiation	O
to	O
down-modulate	O
inflammation	O
.	O

To	O
test	O
whether	O
disordered	O
memory	B-cell_type
T	I-cell_type
cell	I-cell_type
differentiation	O
contributes	O
to	O
the	O
typical	O
Th1-dominated	O
chronic	O
inflammation	O
in	O
RA	O
we	O
investigated	O
differentiation	O
of	O
resting	B-cell_type
CD4+	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
patients	O
with	O
early	O
(	O
6	O
wk	O
to	O
12	O
mo	O
)	O
untreated	O
RA	O
and	O
in	O
age-	O
and	O
sex-matched	O
healthy	O
controls	O
in	O
vitro	O
.	O

No	O
difference	O
in	O
cytokine	B-protein
secretion	O
profiles	O
of	O
freshly	B-cell_type
isolated	I-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
detected	O
between	O
patients	O
and	O
controls	O
.	O

A	O
cell	B-cell_line
culture	I-cell_line
system	I-cell_line
was	O
then	O
employed	O
that	O
permitted	O
the	O
differentiation	O
of	O
Th	B-protein
effectors	I-protein
from	O
resting	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
by	O
short	O
term	O
priming	O
.	O

Marked	O
differences	O
were	O
found	O
in	O
response	O
to	O
priming	O
.	O

Th2	B-cell_line
cells	I-cell_line
could	O
be	O
induced	O
in	O
all	O
healthy	O
controls	O
by	O
priming	O
with	O
anti-CD28	B-protein
in	O
the	O
absence	O
of	O
TCR	B-protein
ligation	O
.	O

By	O
contrast	O
,	O
priming	O
under	O
those	O
conditions	O
resulted	O
in	O
Th2	O
differentiation	O
in	O
only	O
9	O
of	O
24	O
RA	O
patients	O
.	O

Exogenous	O
IL-4	B-protein
could	O
overcome	O
the	O
apparent	O
Th2	O
differentiation	O
defect	O
in	O
seven	O
patients	O
but	O
was	O
without	O
effect	O
in	O
the	O
remaining	O
eight	O
patients	O
.	O

In	O
all	O
patients	O
a	O
marked	O
decrease	O
in	O
IL-2-producing	B-cell_type
cells	I-cell_type
and	O
a	O
significant	O
increase	O
in	O
well-differentiated	O
Th1	B-cell_type
cells	I-cell_type
that	O
produced	O
IFN-gamma	B-protein
but	O
not	O
IL-2	B-protein
were	O
evident	O
after	O
priming	O
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
.	O

The	O
data	O
suggest	O
that	O
CD4+	B-cell_type
memory	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
early	O
untreated	O
RA	O
manifest	O
an	O
intrinsic	O
abnormality	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
specific	O
cytokine-producing	B-cell_type
effector	I-cell_type
cells	I-cell_type
that	O
might	O
contribute	O
to	O
the	O
characteristic	O
Th1-dominated	O
chronic	O
(	O
auto	O
)	O
immune	O
inflammation	O
in	O
RA	O
.	O

``	NULL
Th	NULL
VIVO	NULL
v	NULL
RE	NULL
SEAR	NULL
GCH	NULL
£	NULL
Discover	NULL
More	NULL
Me	NULL
Aa	NULL
meJournal	NULL
f	NULL
Altered	NULL
Memory	NULL
T	NULL
Cell	NULL
Differentiation	NULL
in	NULL
Aﬁlmmunolo	NULL
gy	NULL
Patients	NULL
with	NULL
Early	NULL
Rheumatoid	NULL
Arthritis	NULL
Alla	NULL
Skapenko	NULL
,	NULL
Jorg	NULL
Wendler	NULL
,	NULL
Peter	NULL
E.	NULL
Lipsky	NULL
,	NULL
Joachim	NULL
R.	NULL
220	NULL
l.	NULL
Kalden	NULL
and	NULL
Hendrik	NULL
Schulze-Koops	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
163:491-499	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/163/1/491	NULL
BULK	NULL
ANTIBODIES	NULL
--	NULL
-	NULL
Yen	NULL
LAG	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
61	NULL
articles	NULL
,	NULL
22	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.jimmunol.org/content/163/1/491	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
Altered	NULL
Memory	NULL
T	NULL
Cell	NULL
Differentiation	NULL
in	NULL
Patients	NULL
with	NULL
Early	NULL
Rheumatoid	NULL
Arthritis	NULL
'	NULL
Alla	NULL
Skapenko	NULL
,	NULL
*	NULL
Jorg	NULL
Wendler	NULL
,	NULL
``	NULL
Peter	NULL
E.	NULL
Lipsky	NULL
,	NULL
*	NULL
Joachim	NULL
R.	NULL
Kalden	NULL
,	NULL
*	NULL
and	NULL
Hendrik	NULL
Schulze-Koops*	NULL
``	NULL
*	NULL
The	NULL
chronic	NULL
immune	NULL
response	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
RA	NULL
)	NULL
might	NULL
be	NULL
driven	NULL
by	NULL
activated	NULL
Th1	NULL
cells	NULL
without	NULL
sufficient	NULL
Th2	NULL
cell	NULL
differentiation	NULL
to	NULL
down-modulate	NULL
inflammation	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
disordered	NULL
memory	NULL
T	NULL
cell	NULL
differentiation	NULL
contributes	NULL
to	NULL
the	NULL
typical	NULL
Th1-dominated	NULL
chronic	NULL
inflammation	NULL
in	NULL
RA	NULL
we	NULL
investigated	NULL
differentiation	NULL
of	NULL
resting	NULL
CD4*	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
patients	NULL
with	NULL
early	NULL
(	NULL
6	NULL
wk	NULL
to	NULL
12	NULL
mo	NULL
)	NULL
untreated	NULL
RA	NULL
and	NULL
in	NULL
age-	NULL
and	NULL
sex-matched	NULL
healthy	NULL
controls	NULL
in	NULL
vitro	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
cytokine	NULL
secretion	NULL
profiles	NULL
of	NULL
freshly	NULL
isolated	NULL
memory	NULL
T	NULL
cells	NULL
was	NULL
detected	NULL
between	NULL
patients	NULL
and	NULL
controls	NULL
.	NULL

A	NULL
cell	NULL
culture	NULL
system	NULL
was	NULL
then	NULL
employed	NULL
that	NULL
permitted	NULL
the	NULL
differentiation	NULL
of	NULL
Th	NULL
effectors	NULL
from	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
by	NULL
short	NULL
term	NULL
priming	NULL
.	NULL

Marked	NULL
differences	NULL
were	NULL
found	NULL
in	NULL
response	NULL
to	NULL
priming	NULL
.	NULL

Th2	NULL
cells	NULL
could	NULL
be	NULL
induced	NULL
in	NULL
all	NULL
healthy	NULL
controls	NULL
by	NULL
priming	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
ligation	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
priming	NULL
under	NULL
those	NULL
conditions	NULL
resulted	NULL
in	NULL
Th2	NULL
differentiation	NULL
in	NULL
only	NULL
9	NULL
of	NULL
24	NULL
RA	NULL
patients	NULL
.	NULL

Exogenous	NULL
IL-4	NULL
could	NULL
overcome	NULL
the	NULL
apparent	NULL
Th2	NULL
differentiation	NULL
defect	NULL
in	NULL
seven	NULL
patients	NULL
but	NULL
was	NULL
without	NULL
effect	NULL
in	NULL
the	NULL
remaining	NULL
eight	NULL
patients	NULL
.	NULL

In	NULL
all	NULL
patients	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
IL-2-producing	NULL
cells	NULL
and	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
well-differentiated	NULL
Th1	NULL
cells	NULL
that	NULL
produced	NULL
IFN-y	NULL
but	NULL
not	NULL
IL-2	NULL
were	NULL
evident	NULL
after	NULL
priming	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
.	NULL

The	NULL
data	NULL
suggest	NULL
that	NULL
CD4*	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
early	NULL
untreated	NULL
RA	NULL
manifest	NULL
an	NULL
intrinsic	NULL
abnormality	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
differentiate	NULL
into	NULL
specific	NULL
cytokine-producing	NULL
effector	NULL
cells	NULL
that	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
characteristic	NULL
Th1-dominated	NULL
chronic	NULL
(	NULL
auto	NULL
)	NULL
immune	NULL
inflammation	NULL
in	NULL
RA	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
163	NULL
;	NULL
491-499	NULL
.	NULL

Ithough	NULL
the	NULL
mechanisms	NULL
regulating	NULL
the	NULL
chronic	NULL
autoim-A	NULL
mune	NULL
response	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
(	NULL
RA	NULL
)	NULL
are	NULL
not	NULL
completely	NULL
understood	NULL
,	NULL
considerable	NULL
evidence	NULL
supports	NULL
the	NULL
conclusion	NULL
that	NULL
activated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
initiating	NULL
and	NULL
perpetuating	NULL
the	NULL
chronic	NULL
inflammation	NULL
characteristic	NULL
for	NULL
the	NULL
disease	NULL
(	NULL
1-4	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
their	NULL
distinctive	NULL
cytokine	NULL
secretion	NULL
pattern	NULL
and	NULL
effector	NULL
functions	NULL
,	NULL
human	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
divided	NULL
into	NULL
at	NULL
least	NULL
three	NULL
different	NULL
subsets	NULL
.	NULL

Th1	NULL
cells	NULL
produce	NULL
the	NULL
proin-flammatory	NULL
cytokine	NULL
IFN-y	NULL
,	NULL
IL-2	NULL
,	NULL
and	NULL
TNFE-B	NULL
,	NULL
promote	NULL
macrophage	NULL
activation	NULL
,	NULL
induce	NULL
delayed-type	NULL
hypersensitivity	NULL
,	NULL
and	NULL
are	NULL
involved	NULL
in	NULL
cell-mediated	NULL
immunity	NULL
.	NULL

Th2	NULL
cells	NULL
have	NULL
been	NULL
associated	NULL
with	NULL
down-modulation	NULL
of	NULL
macrophage	NULL
effector	NULL
functions	NULL
,	NULL
they	NULL
produce	NULL
the	NULL
anti-inflammatory	NULL
cytokine	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
and	NULL
IL-13	NULL
,	NULL
and	NULL
mediate	NULL
allergic	NULL
immune	NULL
responses	NULL
(	NULL
5-8	NULL
)	NULL
.	NULL

A	NULL
third	NULL
subset	NULL
,	NULL
designated	NULL
T	NULL
regulatory	NULL
cells	NULL
,	NULL
produces	NULL
mainly	NULL
IL-10	NULL
and	NULL
might	NULL
play	NULL
a	NULL
role	NULL
in	NULL
maintaining	NULL
peripheral	NULL
tolerance	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Imbalances	NULL
in	NULL
the	NULL
ratio	NULL
of	NULL
activated	NULL
Th1	NULL
vs	NULL
Th2	NULL
cells	NULL
have	NULL
been	NULL
associated	NULL
with	NULL
the	NULL
development	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
pathologic	NULL
inflam-	NULL
*Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
LII	NULL
and	NULL
Institute	NULL
for	NULL
Clinical	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Erlangen-Nuremberg	NULL
,	NULL
and	NULL
*Rheumatologische	NULL
Gemeinschaftspraxis	NULL
,	NULL
Erlangen	NULL
,	NULL
Germany	NULL
;	NULL
and	NULL
*Harold	NULL
C.	NULL
Simmons	NULL
Arthritis	NULL
Research	NULL
Center	NULL
,	NULL
Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Texas	NULL
Southwestern	NULL
Medical	NULL
Center	NULL
,	NULL
Dallas	NULL
,	NULL
TX	NULL
75235	NULL
Received	NULL
for	NULL
publication	NULL
February	NULL
12	NULL
,	NULL
1999	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
April	NULL
8	NULL
,	NULL
1999	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
Grant	NULL
Schu	NULL
786/2-1	NULL
.	NULL

?	NULL

Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Hendrik	NULL
Schulze-Koops	NULL
,	NULL
Department	NULL
of	NULL
Internal	NULL
Medicine	NULL
III	NULL
and	NULL
Institute	NULL
for	NULL
Clinical	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Erlangen-Nuremberg	NULL
,	NULL
Glueckstrasse	NULL
4a	NULL
,	NULL
D-91054	NULL
Erlangen	NULL
,	NULL
Germany	NULL
.	NULL

E-mail	NULL
ad-dress	NULL
:	NULL
schulze-koops	NULL
@	NULL
med3.med.uni-erlangen.de	NULL
°	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
RA	NULL
,	NULL
rheumatoid	NULL
arthritis	NULL
;	NULL
DMARD	NULL
,	NULL
disease-modifying	NULL
anti-theumatic	NULL
drug	NULL
;	NULL
ESR	NULL
,	NULL
erythrocyte	NULL
sedimentation	NULL
rate	NULL
;	NULL
CRP	NULL
,	NULL
C-reactive	NULL
protein	NULL
;	NULL
NHS	NULL
,	NULL
normal	NULL
human	NULL
serum	NULL
;	NULL
CD	NULL
,	NULL
cluster	NULL
of	NULL
differentiation	NULL
;	NULL
JAK	NULL
,	NULL
Janus	NULL
kinase	NULL
;	NULL
pTyr	NULL
,	NULL
phosphotyrosine	NULL
.	NULL

Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
matory	NULL
responses	NULL
(	NULL
10-12	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
Th1-mediated	NULL
immunity	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
pathogenesis	NULL
of	NULL
several	NULL
organ-specific	NULL
autoimmune	NULL
diseases	NULL
in	NULL
animals	NULL
(	NULL
13-15	NULL
)	NULL
and	NULL
has	NULL
recently	NULL
been	NULL
implicated	NULL
in	NULL
mediating	NULL
human	NULL
autoimmune	NULL
diseases	NULL
such	NULL
as	NULL
RA	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
elevated	NULL
levels	NULL
of	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
mRNA	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
the	NULL
peripheral	NULL
circulation	NULL
of	NULL
patients	NULL
with	NULL
RA	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
human	NULL
rheumatoid	NULL
synovial	NULL
tissue	NULL
produce	NULL
mainly	NULL
IFN-y	NULL
and	NULL
IL-2	NULL
(	NULL
11	NULL
,	NULL
16	NULL
,	NULL
18-21	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
T	NULL
cells	NULL
producing	NULL
cytokines	NULL
characteristic	NULL
of	NULL
activated	NULL
Th2	NULL
cells	NULL
,	NULL
in	NULL
particular	NULL
IL-4	NULL
,	NULL
were	NULL
rarely	NULL
found	NULL
in	NULL
the	NULL
peripheral	NULL
circulation	NULL
or	NULL
in	NULL
inflamed	NULL
synovial	NULL
tissue	NULL
from	NULL
patients	NULL
with	NULL
RA	NULL
(	NULL
17	NULL
,	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Given	NULL
the	NULL
significance	NULL
that	NULL
differentiated	NULL
effector	NULL
cells	NULL
play	NULL
in	NULL
the	NULL
outcome	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
understand	NULL
the	NULL
mechanisms	NULL
that	NULL
regulate	NULL
the	NULL
development	NULL
of	NULL
T	NULL
effector	NULL
cells	NULL
.	NULL

Cytokines	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
major	NULL
factor	NULL
in	NULL
determining	NULL
Th	NULL
cell	NULL
polarization	NULL
from	NULL
naive	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
Th2	NULL
cells	NULL
arise	NULL
after	NULL
priming	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-4	NULL
(	NULL
23-27	NULL
)	NULL
,	NULL
whereas	NULL
priming	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-4	NULL
initiates	NULL
Th1	NULL
cell	NULL
development	NULL
(	NULL
25	NULL
,	NULL
26	NULL
,	NULL
28	NULL
)	NULL
that	NULL
is	NULL
greatly	NULL
enhanced	NULL
by	NULL
IL-12	NULL
(	NULL
29	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Other	NULL
factors	NULL
with	NULL
a	NULL
regulatory	NULL
capacity	NULL
for	NULL
Th	NULL
cell	NULL
differentiation	NULL
from	NULL
naive	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
such	NULL
as	NULL
the	NULL
intensity	NULL
of	NULL
TCR	NULL
ligation	NULL
during	NULL
priming	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
or	NULL
the	NULL
nature	NULL
and	NULL
intensity	NULL
of	NULL
costimulatory	NULL
signals	NULL
(	NULL
33-36	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
in	NULL
humans	NULL
,	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
can	NULL
also	NULL
be	NULL
primed	NULL
to	NULL
differentiate	NULL
into	NULL
IL-4-producing	NULL
Th2	NULL
cells	NULL
.	NULL

Generation	NULL
of	NULL
Th2	NULL
memory	NULL
effector	NULL
cells	NULL
from	NULL
early	NULL
CD27	NULL
*	NULL
memory	NULL
T	NULL
cells	NULL
was	NULL
dependent	NULL
on	NULL
stimulation	NULL
by	NULL
CD28	NULL
,	NULL
was	NULL
enhanced	NULL
by	NULL
exogenous	NULL
IL-4	NULL
,	NULL
and	NULL
was	NULL
inhibited	NULL
by	NULL
TCR	NULL
ligation	NULL
(	NULL
37	NULL
)	NULL
.	NULL

As	NULL
chronic	NULL
autoimmune	NULL
responses	NULL
are	NULL
perpetuated	NULL
by	NULL
repeatedly	NULL
activated	NULL
memory	NULL
T	NULL
cells	NULL
,	NULL
disordered	NULL
regulation	NULL
of	NULL
memory	NULL
T	NULL
cell	NULL
differentiation	NULL
might	NULL
promote	NULL
the	NULL
pathogenesis	NULL
of	NULL
autoimmune	NULL
diseases	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
large	NULL
numbers	NULL
of	NULL
mature	NULL
memory	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
the	NULL
peripheral	NULL
circulation	NULL
and	NULL
the	NULL
synovial	NULL
tissue	NULL
of	NULL
RA	NULL
patients	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Although	NULL
phenotypically	NULL
mature	NULL
(	NULL
CD4*CD27-CD45RB	NULL
``	NULL
)	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
492	NULL
RA	NULL
fail	NULL
to	NULL
produce	NULL
IL-4	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
those	NULL
from	NULL
healthy	NULL
individuals	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
mature	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
RA	NULL
appear	NULL
to	NULL
differ	NULL
functionally	NULL
from	NULL
mature	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
healthy	NULL
individuals	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mechanisms	NULL
responsible	NULL
for	NULL
these	NULL
functional	NULL
differences	NULL
have	NULL
yet	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

To	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
altered	NULL
memory	NULL
effector	NULL
cell	NULL
differentiation	NULL
contributes	NULL
to	NULL
the	NULL
typical	NULL
Th1-dominated	NULL
immune	NULL
response	NULL
in	NULL
RA	NULL
,	NULL
we	NULL
investigated	NULL
memory	NULL
T	NULL
cell	NULL
differentiation	NULL
in	NULL
RA	NULL
patients	NULL
in	NULL
vitro	NULL
.	NULL

A	NULL
culture	NULL
system	NULL
was	NULL
employed	NULL
to	NULL
assess	NULL
Th1	NULL
and	NULL
Th2	NULL
cell	NULL
differentiation	NULL
in	NULL
vitro	NULL
using	NULL
highly	NULL
purified	NULL
populations	NULL
of	NULL
CD4	NULL
*	NULL
memory	NULL
T	NULL
cells	NULL
that	NULL
has	NULL
previously	NULL
been	NULL
used	NULL
to	NULL
identify	NULL
the	NULL
signals	NULL
controlling	NULL
this	NULL
process	NULL
effectively	NULL
(	NULL
37	NULL
)	NULL
.	NULL

As	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
chronic	NULL
activation	NULL
might	NULL
cause	NULL
fixation	NULL
of	NULL
the	NULL
Th	NULL
phenotype	NULL
(	NULL
40	NULL
)	NULL
,	NULL
RA	NULL
patients	NULL
were	NULL
chosen	NULL
with	NULL
early	NULL
disease	NULL
(	NULL
6	NULL
wk	NULL
to	NULL
12	NULL
mo	NULL
)	NULL
.	NULL

To	NULL
eliminate	NULL
the	NULL
influence	NULL
of	NULL
drugs	NULL
on	NULL
the	NULL
generation	NULL
of	NULL
polarized	NULL
effector	NULL
cells	NULL
,	NULL
patients	NULL
were	NULL
excluded	NULL
who	NULL
had	NULL
previously	NULL
been	NULL
treated	NULL
with	NULL
disease-modifying	NULL
-	NULL
anti-rheumatic	NULL
drugs	NULL
(	NULL
DMARDs	NULL
)	NULL
,	NULL
including	NULL
methotrexate	NULL
,	NULL
or	NULL
corticosteroids	NULL
.	NULL

Whereas	NULL
Th2	NULL
cell	NULL
differentiation	NULL
could	NULL
be	NULL
induced	NULL
in	NULL
all	NULL
healthy	NULL
individuals	NULL
,	NULL
RA	NULL
patients	NULL
were	NULL
identified	NULL
with	NULL
an	NULL
impaired	NULL
ability	NULL
to	NULL
generate	NULL
Th2	NULL
effectors	NULL
.	NULL

In	NULL
some	NULL
of	NULL
the	NULL
patients	NULL
exogenous	NULL
IL-4	NULL
could	NULL
overcome	NULL
the	NULL
apparent	NULL
T	NULL
cell	NULL
differentiation	NULL
defect	NULL
.	NULL

However	NULL
,	NULL
in	NULL
eight	NULL
of	NULL
24	NULL
patients	NULL
,	NULL
no	NULL
Th2	NULL
effectors	NULL
could	NULL
be	NULL
induced	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
all	NULL
RA	NULL
patients	NULL
manifested	NULL
increased	NULL
in	NULL
vitro	NULL
differentiation	NULL
into	NULL
specialized	NULL
IFN-y-positive	NULL
Th1	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
imply	NULL
an	NULL
abnormal	NULL
memory	NULL
Th	NULL
effector	NULL
cell	NULL
differentiation	NULL
in	NULL
RA	NULL
that	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
characteristic	NULL
Th1-dominated	NULL
rheumatoid	NULL
inflammation	NULL
and	NULL
,	NULL
thus	NULL
,	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
RA	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Abs	NULL
and	NULL
reagents	NULL
The	NULL
following	NULL
mAbs	NULL
were	NULL
used	NULL
for	NULL
purification	NULL
of	NULL
cells	NULL
,	NULL
for	NULL
cell	NULL
culture	NULL
and	NULL
staining	NULL
:	NULL
anti-CD3	NULL
(	NULL
OKT3	NULL
)	NULL
,	NULL
anti-CD8	NULL
(	NULL
OKT8	NULL
)	NULL
,	NULL
anti-HLA-DR	NULL
(	NULL
L243	NULL
)	NULL
,	NULL
and	NULL
P1.17	NULL
(	NULL
control	NULL
IgG2a	NULL
mAb	NULL
,	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Manassas	NULL
,	NULL
VA	NULL
)	NULL
;	NULL
anti-CD16	NULL
,	NULL
anti-CD19	NULL
,	NULL
FITC-conjugated	NULL
anti-CD25	NULL
,	NULL
FITC-labeled	NULL
anti-CD30	NULL
,	NULL
and	NULL
FITC-labeled	NULL
anti-HLA-DR	NULL
(	NULL
Dako	NULL
Diagnostika	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
;	NULL
anti-CD45RA	NULL
(	NULL
111-1€5	NULL
,	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
Ramon	NULL
Vilella	NULL
,	NULL
Bar-celona	NULL
,	NULL
Spain	NULL
)	NULL
;	NULL
FITC-conjugated	NULL
anti-CD3	NULL
,	NULL
PE-labeled	NULL
anti-CD4	NULL
,	NULL
and	NULL
PE-labeled	NULL
anti-CD45RO	NULL
(	NULL
UCHL-1	NULL
,	NULL
Sigma-Aldrich	NULL
,	NULL
Deisenhofen	NULL
,	NULL
Germany	NULL
)	NULL
;	NULL
and	NULL
anti-CD28	NULL
(	NULL
28.2	NULL
)	NULL
,	NULL
FITC-labeled	NULL
anti-CD69	NULL
,	NULL
PE-labeled	NULL
anti-IL-4	NULL
(	NULL
MP4-25D2	NULL
)	NULL
,	NULL
PE-labeled	NULL
anti-IL-2	NULL
(	NULL
MQ1-17H12	NULL
)	NULL
,	NULL
and	NULL
FITC-labeled	NULL
anti-IFN-y	NULL
(	NULL
48.B3	NULL
,	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Abs	NULL
used	NULL
for	NULL
immunoprecipitation	NULL
and	NULL
immunoblotting	NULL
were	NULL
anti-STAT6	NULL
(	NULL
S-20	NULL
and	NULL
M-20	NULL
)	NULL
and	NULL
anti-phosphotyrosine	NULL
mAb	NULL
(	NULL
PY20	NULL
;	NULL
all	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Study	NULL
population	NULL
The	NULL
study	NULL
population	NULL
consisted	NULL
of	NULL
24	NULL
patients	NULL
with	NULL
an	NULL
established	NULL
diagnosis	NULL
of	NULL
RA	NULL
as	NULL
defined	NULL
by	NULL
the	NULL
1987	NULL
revised	NULL
criteria	NULL
of	NULL
the	NULL
American	NULL
College	NULL
of	NULL
Rheumatology	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
RA	NULL
(	NULL
41	NULL
)	NULL
.	NULL

All	NULL
patients	NULL
were	NULL
required	NULL
to	NULL
have	NULL
symptoms	NULL
of	NULL
the	NULL
disease	NULL
for	NULL
<	NULL
12	NULL
mo	NULL
and	NULL
had	NULL
not	NULL
previously	NULL
been	NULL
treated	NULL
with	NULL
corticosteroids	NULL
,	NULL
DMARDs	NULL
,	NULL
or	NULL
methotrexate	NULL
.	NULL

The	NULL
mean	NULL
age	NULL
of	NULL
the	NULL
study	NULL
population	NULL
was	NULL
52.9	NULL
yr	NULL
(	NULL
range	NULL
,	NULL
30-71	NULL
yr	NULL
)	NULL
with	NULL
a	NULL
mean	NULL
disease	NULL
duration	NULL
of	NULL
5.9	NULL
+	NULL
3.8	NULL
mo	NULL
(	NULL
range	NULL
,	NULL
6	NULL
wk	NULL
to	NULL
12	NULL
mo	NULL
)	NULL
.	NULL

Sixteen	NULL
of	NULL
the	NULL
twenty-four	NULL
patients	NULL
had	NULL
elevated	NULL
erythrocyte	NULL
sedimentation	NULL
rates	NULL
(	NULL
ESR	NULL
;	NULL
>	NULL
20	NULL
mm/h	NULL
;	NULL
Westergren	NULL
)	NULL
,	NULL
14	NULL
patients	NULL
had	NULL
increased	NULL
levels	NULL
of	NULL
C-reactive	NULL
protein	NULL
(	NULL
CRP	NULL
;	NULL
>	NULL
5	NULL
mg/l	NULL
)	NULL
,	NULL
and	NULL
17	NULL
of	NULL
the	NULL
patients	NULL
were	NULL
seropositive	NULL
for	NULL
IgM	NULL
rheumatoid	NULL
factor	NULL
.	NULL

The	NULL
clinical	NULL
and	NULL
demographic	NULL
data	NULL
of	NULL
the	NULL
patients	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
I	NULL
.	NULL

Ten	NULL
healthy	NULL
age-	NULL
and	NULL
sex-matched	NULL
volunteers	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
.	NULL

The	NULL
study	NULL
protocol	NULL
was	NULL
approved	NULL
by	NULL
the	NULL
review	NULL
board	NULL
of	NULL
the	NULL
University	NULL
of	NULL
Erlangen-Nuremberg	NULL
,	NULL
and	NULL
written	NULL
informed	NULL
consent	NULL
was	NULL
obtained	NULL
from	NULL
all	NULL
individuals	NULL
before	NULL
entering	NULL
the	NULL
study	NULL
.	NULL

Memory	NULL
T	NULL
cell	NULL
preparation	NULL
PBMC	NULL
were	NULL
obtained	NULL
from	NULL
heparinized	NULL
venous	NULL
blood	NULL
by	NULL
centrifugation	NULL
(	NULL
30	NULL
min	NULL
,	NULL
400	NULL
X	NULL
g	NULL
)	NULL
over	NULL
a	NULL
Ficoll-Hypaque	NULL
gradient	NULL
(	NULL
Sigma-Aldrich	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
with	NULL
saline	NULL
and	NULL
subsequently	NULL
incubated	NULL
with	NULL
neuraminidase-treated	NULL
sheep	NULL
RBC	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
rosette-positive	NULL
cells	NULL
were	NULL
further	NULL
purified	NULL
by	NULL
negative	NULL
selection	NULL
panning	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
37	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
saturating	NULL
amounts	NULL
of	NULL
mAb	NULL
against	NULL
CD8	NULL
,	NULL
CD19	NULL
,	NULL
CD16	NULL
,	NULL
T	NULL
CELL	NULL
DIFFERENTIATION	NULL
IN	NULL
RHEUMATOID	NULL
ARTHRITIS	NULL
Table	NULL
I	NULL
.	NULL

-	NULL
Study	NULL
population	NULL
``	NULL
n	NULL
24	NULL
Sex	NULL
(	NULL
M/F	NULL
)	NULL
8/16	NULL
Age	NULL
(	NULL
yr	NULL
)	NULL
52.9	NULL
+	NULL
13.4	NULL
Disease	NULL
duration	NULL
(	NULL
mo	NULL
)	NULL
5.9	NULL
+	NULL
3.8	NULL
Erythrocyte	NULL
sedimentation	NULL
rate	NULL
(	NULL
mm/h	NULL
)	NULL
22	NULL
[	NULL
1	NULL
;	NULL
60	NULL
]	NULL
C-reactive	NULL
protein	NULL
(	NULL
mg/l	NULL
)	NULL
8	NULL
[	NULL
3	NULL
;	NULL
82	NULL
]	NULL
Rheumatoid	NULL
factor	NULL
(	NULL
IU/ml	NULL
)	NULL
22	NULL
[	NULL
10	NULL
;	NULL
339	NULL
]	NULL
HLA-DRB1*04	NULL
or	NULL
*01	NULL
positive	NULL
12	NULL
``	NULL
Data	NULL
are	NULL
presented	NULL
as	NULL
absolute	NULL
values	NULL
,	NULL
mean	NULL
+	NULL
SD	NULL
or	NULL
median	NULL
[	NULL
range	NULL
]	NULL
.	NULL

HLA-DR	NULL
,	NULL
and	NULL
CD4SRA	NULL
for	NULL
15	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Eggenstein	NULL
,	NULL
Germany	NULL
)	NULL
containing	NULL
2	NULL
%	NULL
pooled	NULL
normal	NULL
human	NULL
serum	NULL
(	NULL
NHS	NULL
)	NULL
,	NULL
washed	NULL
and	NULL
allowed	NULL
to	NULL
bind	NULL
to	NULL
plastic	NULL
petri	NULL
dishes	NULL
(	NULL
Greiner	NULL
,	NULL
Frickenhausen	NULL
,	NULL
Germany	NULL
)	NULL
coated	NULL
with	NULL
goat	NULL
anti-mouse	NULL
Igs	NULL
(	NULL
Cappel	NULL
,	NULL
West	NULL
Chester	NULL
,	NULL
PA	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Recovered	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
containing	NULL
10	NULL
%	NULL
NHS	NULL
.	NULL

The	NULL
homogeneity	NULL
and	NULL
purity	NULL
of	NULL
the	NULL
recovered	NULL
cells	NULL
were	NULL
assessed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Typically	NULL
,	NULL
>	NULL
95	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
positive	NULL
for	NULL
CD3	NULL
and	NULL
CD4	NULL
,	NULL
>	NULL
90	NULL
%	NULL
stained	NULL
brightly	NULL
with	NULL
an	NULL
mAb	NULL
to	NULL
CD4SRO	NULL
,	NULL
and	NULL
>	NULL
98	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
viable	NULL
after	NULL
the	NULL
purification	NULL
procedure	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
negative	NULL
for	NULL
the	NULL
activation	NULL
markers	NULL
CD25	NULL
,	NULL
CD30	NULL
,	NULL
CD69	NULL
,	NULL
and	NULL
HLA-DR.	NULL
Generation	NULL
of	NULL
memory	NULL
effector	NULL
T	NULL
cells	NULL
All	NULL
cell	NULL
cultures	NULL
were	NULL
conducted	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
penicillin	NULL
G	NULL
(	NULL
100	NULL
IU/ml	NULL
)	NULL
,	NULL
streptomycin	NULL
(	NULL
100	NULL
Lug/m	NULL
!	NULL
)	NULL

,	NULL
L-glutamine	NULL
(	NULL
2	NULL
mM	NULL
)	NULL
,	NULL
and	NULL
10	NULL
%	NULL
NHS	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
containing	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

For	NULL
the	NULL
generation	NULL
of	NULL
memory	NULL
effector	NULL
T	NULL
cells	NULL
,	NULL
a	NULL
previously	NULL
described	NULL
multistep	NULL
ex	NULL
vivo	NULL
cell	NULL
culture	NULL
system	NULL
was	NULL
used	NULL
(	NULL
37	NULL
)	NULL
that	NULL
permitted	NULL
the	NULL
differentiation	NULL
of	NULL
effector	NULL
T	NULL
cells	NULL
by	NULL
short	NULL
term	NULL
mitogenic	NULL
stimulation	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
mature	NULL
effector	NULL
cells	NULL
were	NULL
generated	NULL
by	NULL
priming	NULL
purified	NULL
CD4	NULL
*	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
flat-bottom	NULL
cell	NULL
culture	NULL
plates	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
0.5	NULL
X	NULL
10°	NULL
cells/ml	NULL
with	NULL
1	NULL
pg/ml	NULL
anti-CD28	NULL
mAb	NULL
and	NULL
10	NULL
U/ml	NULL
recombinant	NULL
human	NULL
IL-2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
recombinant	NULL
human	NULL
IL-4	NULL
(	NULL
31.25	NULL
ng/ml	NULL
)	NULL
.	NULL

When	NULL
anti-CD3	NULL
stimulation	NULL
was	NULL
used	NULL
during	NULL
priming	NULL
,	NULL
the	NULL
plates	NULL
were	NULL
coated	NULL
with	NULL
OKT3	NULL
(	NULL
1	NULL
ug/ml	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
9.5	NULL
)	NULL
for	NULL
24	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Unbound	NULL
mAb	NULL
was	NULL
removed	NULL
by	NULL
washing	NULL
the	NULL
plates	NULL
with	NULL
PBS	NULL
immediately	NULL
before	NULL
the	NULL
cells	NULL
were	NULL
added	NULL
.	NULL

After	NULL
5	NULL
days	NULL
of	NULL
priming	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
counted	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
rested	NULL
for	NULL
60	NULL
h	NULL
at	NULL
37°C	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
X	NULL
10°	NULL
cells/ml	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
U/ml	NULL
rIL-2	NULL
.	NULL

The	NULL
phenotype	NULL
of	NULL
the	NULL
effector	NULL
populations	NULL
as	NULL
defined	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
cells	NULL
to	NULL
produce	NULL
cytokines	NULL
was	NULL
determined	NULL
by	NULL
intracellular	NULL
flow	NULL
cytometry	NULL
after	NULL
maximal	NULL
mitogenic	NULL
stimulation	NULL
and	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
starting	NULL
population	NULL
.	NULL

By	NULL
assessing	NULL
Th	NULL
cell	NULL
differentiation	NULL
in	NULL
serial	NULL
controls	NULL
,	NULL
the	NULL
assay	NULL
was	NULL
found	NULL
to	NULL
be	NULL
highly	NULL
reproducible	NULL
in	NULL
individual	NULL
healthy	NULL
donors	NULL
and	NULL
stable	NULL
over	NULL
time	NULL
.	NULL

Flow	NULL
cytometry	NULL
Cells	NULL
(	NULL
1	NULL
X	NULL
10°/sample	NULL
)	NULL
were	NULL
stained	NULL
with	NULL
saturating	NULL
amounts	NULL
of	NULL
directly	NULL
labeled	NULL
mAb	NULL
and	NULL
analyzed	NULL
by	NULL
FACS	NULL
(	NULL
EPICS	NULL
,	NULL
Beckman	NULL
Coulter	NULL
,	NULL
Fullerton	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
inherent	NULL
capacity	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
cytokine	NULL
production	NULL
and	NULL
to	NULL
bypass	NULL
proximal	NULL
signaling	NULL
events	NULL
after	NULL
TCR/CD3	NULL
activation	NULL
that	NULL
have	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
impaired	NULL
in	NULL
synovial	NULL
T	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
(	NULL
43	NULL
)	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
(	NULL
1	NULL
mM	NULL
;	NULL
Calbiochem	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
20	NULL
ng/ml	NULL
;	NULL
Sigma-Aldrich	NULL
)	NULL
for	NULL
5	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
M	NULL
monensin	NULL
(	NULL
Sigma-Aldrich	NULL
)	NULL
to	NULL
prevent	NULL
secretion	NULL
of	NULL
cytokines	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
,	NULL
fixed	NULL
with	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
(	NULL
Sigma-Aldrich	NULL
)	NULL
in	NULL
PBS	NULL
for	NULL
15	NULL
min	NULL
at	NULL
37°C	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
in	NULL
10	NULL
%	NULL
DMSO/PBS	NULL
until	NULL
analysis	NULL
.	NULL

Cells	NULL
were	NULL
permeabilized	NULL
with	NULL
0.1	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
saponin	NULL
(	NULL
Sigma-Aldrich	NULL
)	NULL
in	NULL
2	NULL
%	NULL
FCS/PBS	NULL
.	NULL

Nonspecific	NULL
binding	NULL
sites	NULL
were	NULL
blocked	NULL
with	NULL
4	NULL
%	NULL
mouse	NULL
and	NULL
rat	NULL
serum	NULL
.	NULL

Cytoplasmic	NULL
cytokines	NULL
were	NULL
detected	NULL
by	NULL
staining	NULL
with	NULL
directly	NULL
labeled	NULL
mAb	NULL
against	NULL
human	NULL
cytokines	NULL
for	NULL
25	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
with	NULL
0.1	NULL
%	NULL
saponin/2	NULL
%	NULL
FCS/PBS	NULL
,	NULL
resuspended	NULL
in	NULL
2	NULL
%	NULL
FCS/	NULL
PBS	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Unstimulated	NULL
cells	NULL
that	NULL
were	NULL
identically	NULL
stained	NULL
and	NULL
stimulated	NULL
cells	NULL
that	NULL
were	NULL
permeabilized	NULL
or	NULL
not	NULL
but	NULL
stained	NULL
with	NULL
irrelevant	NULL
mAb	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
for	NULL
determining	NULL
background	NULL
fluorescence	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
Western	NULL
blotting	NULL
Purified	NULL
CD4*	NULL
memory	NULL
T	NULL
cells	NULL
(	NULL
2-5	NULL
X	NULL
10	NULL
``	NULL
;	NULL
100	NULL
x	NULL
10°/ml	NULL
)	NULL
were	NULL
deprived	NULL
of	NULL
serum	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
and	NULL
were	NULL
stimulated	NULL
with	NULL
rIL-4	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
deoxycholate	NULL
,	NULL
1	NULL
%	NULL
SDS	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
,	NULL
10	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Table	NULL
II	NULL
.	NULL

-	NULL
Frequency	NULL
of	NULL
cytokine	NULL
producing	NULL
peripheral	NULL
blood	NULL
CD4*	NULL
memory	NULL
T	NULL
cells	NULL
``	NULL
RA	NULL
Patients	NULL
Healthy	NULL
Controls	NULL
IL-2	NULL
78.5	NULL
+	NULL
5.4	NULL
79.2	NULL
+	NULL
8.2	NULL
IFNy	NULL
30.2	NULL
+	NULL
7.0	NULL
30.0	NULL
+	NULL
8.7	NULL
IFN-y	NULL
``	NULL
°®	NULL
,	NULL
IL-4	NULL
``	NULL
``	NULL
(	NULL
Th1	NULL
)	NULL
28.6	NULL
+	NULL
6.6	NULL
28.3	NULL
+	NULL
8.1	NULL
IL-4	NULL
4.6	NULL
+	NULL
1.5	NULL
4.7	NULL
£	NULL
1.9	NULL
IL-4	NULL
``	NULL
°	NULL
,	NULL
IFN-y	NULL
``	NULL
*	NULL
(	NULL
Th2	NULL
)	NULL
3.0	NULL
+	NULL
0.9	NULL
3.2	NULL
+	NULL
1.6	NULL
``	NULL
Highly	NULL
purified	NULL
resting	NULL
peripheral	NULL
blood	NULL
CD4*	NULL
memory	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
h	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
double	NULL
stained	NULL
with	NULL
mAbs	NULL
to	NULL
IFN-y	NULL
and	NULL
IL-2	NULL
or	NULL
IL-4	NULL
,	NULL
and	NULL
intracellular	NULL
cytokines	NULL
were	NULL
detected	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
differences	NULL
between	NULL
RA	NULL
patients	NULL
(	NULL
n	NULL
=	NULL
24	NULL
)	NULL
and	NULL
healthy	NULL
controls	NULL
(	NULL
r	NULL
=	NULL
10	NULL
)	NULL
were	NULL
not	NULL
statistically	NULL
significant	NULL
(	NULL
two-tailed	NULL
Student	NULL
's	NULL
f	NULL
test	NULL
)	NULL
.	NULL

aprotinin	NULL
,	NULL
10	NULL
pg/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
100	NULL
pg/ml	NULL
PMSF	NULL
in	NULL
PBS	NULL
)	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
precleared	NULL
with	NULL
normal	NULL
mouse	NULL
serum	NULL
and	NULL
incubated	NULL
with	NULL
primary	NULL
Ab	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

Immune	NULL
complexes	NULL
were	NULL
precipitated	NULL
with	NULL
recombinant	NULL
protein	NULL
A	NULL
agarose	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
lysis	NULL
buffer	NULL
,	NULL
and	NULL
eluted	NULL
with	NULL
SDS-PAGE	NULL
loading	NULL
buffer	NULL
.	NULL

Proteins	NULL
were	NULL
separated	NULL
in	NULL
a	NULL
7	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
and	NULL
transferred	NULL
onto	NULL
nitrocellulose	NULL
.	NULL

After	NULL
blocking	NULL
of	NULL
nonspecific	NULL
binding	NULL
sites	NULL
(	NULL
5	NULL
%	NULL
milk	NULL
powder	NULL
and	NULL
0.05	NULL
%	NULL
Tween-20	NULL
in	NULL
PBS	NULL
)	NULL
,	NULL
the	NULL
blots	NULL
were	NULL
probed	NULL
with	NULL
specific	NULL
Abs	NULL
for	NULL
STAT6	NULL
or	NULL
phosphotyrosine	NULL
(	NULL
PY20	NULL
)	NULL
and	NULL
developed	NULL
with	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

Statistical	NULL
analysis	NULL
Differences	NULL
in	NULL
data	NULL
distribution	NULL
were	NULL
analyzed	NULL
by	NULL
two-tailed	NULL
Student	NULL
's	NULL
f	NULL
tests	NULL
for	NULL
comparison	NULL
of	NULL
frequencies	NULL
of	NULL
cells	NULL
producing	NULL
particular	NULL
cytokines	NULL
between	NULL
healthy	NULL
individuals	NULL
and	NULL
RA	NULL
patients	NULL
,	NULL
by	NULL
paired	NULL
two-tailed	NULL
1	NULL
tests	NULL
for	NULL
comparison	NULL
of	NULL
Th	NULL
subsets	NULL
in	NULL
effector	NULL
populations	NULL
with	NULL
the	NULL
starting	NULL
populations	NULL
within	NULL
the	NULL
same	NULL
group	NULL
of	NULL
patients	NULL
or	NULL
healthy	NULL
controls	NULL
,	NULL
and	NULL
by	NULL
Fisher	NULL
's	NULL
exact	NULL
test	NULL
for	NULL
comparison	NULL
of	NULL
the	NULL
frequencies	NULL
of	NULL
HLA-DRB1*01-	NULL
or	NULL
*04-positive	NULL
individuals	NULL
within	NULL
different	NULL
patient	NULL
groups	NULL
.	NULL

p	NULL
<	NULL
0.05	NULL
was	NULL
considered	NULL
significant	NULL
.	NULL

Results	NULL
Th1/Th2	NULL
cytokines	NULL
in	NULL
resting	NULL
CD4	NULL
``	NULL
peripheral	NULL
blood	NULL
memory	NULL
T	NULL
cells	NULL
after	NULL
in	NULL
vitro	NULL
stimulation	NULL
To	NULL
assess	NULL
the	NULL
inherent	NULL
capacity	NULL
of	NULL
resting	NULL
peripheral	NULL
blood	NULL
CD4	NULL
*	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
and	NULL
healthy	NULL
controls	NULL
to	NULL
produce	NULL
cytokines	NULL
,	NULL
freshly	NULL
purified	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
vitro	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

As	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
TCR-mediated	NULL
signaling	NULL
in	NULL
RA	NULL
synovial	NULL
T	NULL
cells	NULL
might	NULL
be	NULL
impaired	NULL
with	NULL
respect	NULL
to	NULL
phosphorylation	NULL
of	NULL
the	NULL
TCR	NULL
{	NULL
-chain	NULL
(	NULL
43	NULL
)	NULL
,	NULL
the	NULL
cytokine	NULL
secretion	NULL
pattern	NULL
of	NULL
cells	NULL
was	NULL
analyzed	NULL
throughout	NULL
the	NULL
study	NULL
after	NULL
493	NULL
stimulation	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
which	NULL
bypasses	NULL
the	NULL
most	NULL
proximal	NULL
signaling	NULL
events	NULL
after	NULL
TCR/CD3	NULL
engagement	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
the	NULL
cytokine	NULL
secretion	NULL
pattern	NULL
was	NULL
found	NULL
between	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
and	NULL
cells	NULL
isolated	NULL
from	NULL
healthy	NULL
controls	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
frequencies	NULL
of	NULL
Th1	NULL
cells	NULL
(	NULL
IFN-y-positive	NULL
,	NULL
IL-4-negative	NULL
)	NULL
or	NULL
Th2	NULL
cells	NULL
(	NULL
IL-4-positive	NULL
,	NULL
IFN-y-negative	NULL
)	NULL
in	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
were	NULL
similar	NULL
in	NULL
patients	NULL
and	NULL
controls	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Consequently	NULL
,	NULL
resting	NULL
CD4*	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
and	NULL
healthy	NULL
individuals	NULL
expressed	NULL
similar	NULL
Th1/Th2	NULL
cell	NULL
ratios	NULL
after	NULL
in	NULL
vitro	NULL
stimulation	NULL
(	NULL
10.5	NULL
+	NULL
5.4	NULL
vs	NULL
9.1	NULL
+	NULL
3.6	NULL
in	NULL
RA	NULL
patients	NULL
and	NULL
controls	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
no	NULL
differences	NULL
were	NULL
detected	NULL
between	NULL
RA	NULL
patients	NULL
and	NULL
controls	NULL
with	NULL
respect	NULL
to	NULL
cells	NULL
producing	NULL
IL-4	NULL
and	NULL
IFN-y	NULL
,	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
,	NULL
IFN-y	NULL
but	NULL
no	NULL
IL-2	NULL
,	NULL
or	NULL
IL-2	NULL
but	NULL
no	NULL
IFN-y	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Th2	NULL
memory	NULL
effector	NULL
cell	NULL
generation	NULL
in	NULL
healthy	NULL
controls	NULL
To	NULL
analyze	NULL
Th2	NULL
memory	NULL
cell	NULL
differentiation	NULL
in	NULL
RA	NULL
patients	NULL
we	NULL
first	NULL
established	NULL
the	NULL
optimal	NULL
conditions	NULL
for	NULL
Th2	NULL
generation	NULL
in	NULL
a	NULL
group	NULL
of	NULL
healthy	NULL
individuals	NULL
who	NULL
were	NULL
age-	NULL
and	NULL
sex-matched	NULL
with	NULL
RA	NULL
patients	NULL
.	NULL

Purified	NULL
CD4	NULL
*	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
healthy	NULL
individuals	NULL
were	NULL
primed	NULL
under	NULL
various	NULL
conditions	NULL
that	NULL
have	NULL
previously	NULL
been	NULL
demonstrated	NULL
to	NULL
regulate	NULL
Th2	NULL
effector	NULL
generation	NULL
from	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
,	NULL
namely	NULL
stimulation	NULL
with	NULL
CD28	NULL
and	NULL
IL-4	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
TCR	NULL
ligation	NULL
(	NULL
37	NULL
)	NULL
.	NULL

The	NULL
cytokine	NULL
secretion	NULL
pattern	NULL
of	NULL
freshly	NULL
isolated	NULL
and	NULL
ex	NULL
vivo	NULL
differentiated	NULL
memory	NULL
effector	NULL
cells	NULL
from	NULL
one	NULL
healthy	NULL
individual	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Th2	NULL
cell	NULL
frequencies	NULL
could	NULL
not	NULL
be	NULL
increased	NULL
by	NULL
priming	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
(	NULL
3.1	NULL
+	NULL
1.2	NULL
%	NULL
in	NULL
primed	NULL
cells	NULL
compared	NULL
with	NULL
3.2	NULL
+	NULL
1.6	NULL
%	NULL
in	NULL
freshly	NULL
isolated	NULL
cells	NULL
in	NULL
the	NULL
entire	NULL
group	NULL
of	NULL
healthy	NULL
indi-viduals	NULL
;	NULL
Table	NULL
III	NULL
)	NULL
and	NULL
were	NULL
only	NULL
slightly	NULL
increased	NULL
when	NULL
exogenous	NULL
IL-4	NULL
was	NULL
added	NULL
during	NULL
priming	NULL
(	NULL
4.2	NULL
+	NULL
1.8	NULL
%	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
priming	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
ligation	NULL
induced	NULL
Th2	NULL
cell	NULL
differentiation	NULL
and	NULL
significantly	NULL
increased	NULL
the	NULL
Th2	NULL
cell	NULL
population	NULL
to	NULL
5.7	NULL
+	NULL
1.3	NULL
%	NULL
(	NULL
p	NULL
<	NULL
0.04	NULL
,	NULL
compared	NULL
with	NULL
fresh	NULL
cells	NULL
)	NULL
.	NULL

Priming	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
IL-4	NULL
further	NULL
increased	NULL
the	NULL
Th2	NULL
cell	NULL
frequencies	NULL
to	NULL
9.7	NULL
+	NULL
2.17	NULL
%	NULL
(	NULL
p	NULL
<	NULL
0.006	NULL
vs	NULL
fresh	NULL
cells	NULL
;	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
stressed	NULL
that	NULL
in	NULL
all	NULL
healthy	NULL
individuals	NULL
,	NULL
increased	NULL
numbers	NULL
of	NULL
Th2	NULL
effector	NULL
cells	NULL
could	NULL
be	NULL
generated	NULL
from	NULL
resting	NULL
peripheral	NULL
blood	NULL
CD4	NULL
*	NULL
memory	NULL
T	NULL
cells	NULL
by	NULL
priming	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
engagement	NULL
,	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
Th2	NULL
cells	NULL
of	NULL
at	NULL
least	NULL
50	NULL
%	NULL
routinely	NULL
noted	NULL
.	NULL

Furthermore	NULL
,	NULL
exogenous	NULL
IL-4	NULL
enhanced	NULL
the	NULL
efficiency	NULL
of	NULL
memory	NULL
effector	NULL
T	NULL
cells	NULL
after	NULL
priming	NULL
with	NULL
fresh	NULL
memory	NULL
T	NULL
cells	NULL
anti-CD3	NULL
+	NULL
anti-CD28	NULL
anti-CD28	NULL
anti-CD28	NULL
+	NULL
rIL-4	NULL
IL-4	NULL
FIGURE	NULL
1	NULL
.	NULL

IFN-y	NULL
Th2	NULL
differentiation	NULL
of	NULL
memory	NULL
cells	NULL
in	NULL
healthy	NULL
individuals	NULL
.	NULL

CD4	NULL
*	NULL
memory	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
a	NULL
healthy	NULL
donor	NULL
.	NULL

Effector	NULL
cells	NULL
were	NULL
generated	NULL
by	NULL
priming	NULL
for	NULL
5	NULL
days	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
and	NULL
a	NULL
mAb	NULL
to	NULL
CD28	NULL
or	NULL
with	NULL
anti-CD28	NULL
without	NULL
ligation	NULL
of	NULL
the	NULL
TCR	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
IL-4	NULL
.	NULL

Cytoplasmic	NULL
cytokines	NULL
were	NULL
detected	NULL
by	NULL
flow	NULL
cytometry	NULL
after	NULL
maximum	NULL
stimulation	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
numbers	NULL
indicate	NULL
the	NULL
percentage	NULL
of	NULL
cytokine-producing	NULL
cells	NULL
from	NULL
the	NULL
total	NULL
population	NULL
of	NULL
gated	NULL
viable	NULL
lymphocytes	NULL
.	NULL

Demonstrated	NULL
is	NULL
a	NULL
representative	NULL
cytokine	NULL
secretion	NULL
pattern	NULL
of	NULL
freshly	NULL
isolated	NULL
and	NULL
primed	NULL
effector	NULL
cells	NULL
from	NULL
one	NULL
of	NULL
the	NULL
10	NULL
healthy	NULL
controls	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
494	NULL
T	NULL
CELL	NULL
DIFFERENTIATION	NULL
IN	NULL
RHEUMATOID	NULL
ARTHRITIS	NULL
Table	NULL
III	NULL
.	NULL

-	NULL
Frequency	NULL
of	NULL
Th2	NULL
cells	NULL
in	NULL
resting	NULL
and	NULL
effector	NULL
memory	NULL
populations	NULL
``	NULL
Effector	NULL
Cells	NULL
Primed	NULL
with	NULL
Anti-CD28	NULL
Anti-CD28	NULL
n	NULL
Resting	NULL
Cells	NULL
anti-CD3	NULL
Anti-CD28	NULL
rIL-4	NULL
Healthy	NULL
controls	NULL
10	NULL
3.2	NULL
+	NULL
1.6	NULL
3.1	NULL
+	NULL
1.2	NULL
5.7	NULL
£1.39	NULL
9.7	NULL
+	NULL
2.7	NULL
»	NULL
RA	NULL
patients®	NULL
Group	NULL
I	NULL
9	NULL
3.1	NULL
+	NULL
1.0	NULL
7.9	NULL
+	NULL
5.49	NULL
10.6	NULL
+	NULL
8.3*	NULL
14.8	NULL
+	NULL
10.0	NULL
``	NULL
Group	NULL
II	NULL
7	NULL
3.2	NULL
+	NULL
0.5	NULL
2.8	NULL
+	NULL
1.0	NULL
3.4	NULL
+	NULL
0.8	NULL
7.0	NULL
+	NULL
2.2	NULL
``	NULL
Group	NULL
II	NULL
8	NULL
3.0	NULL
+	NULL
1.2	NULL
3.1	NULL
+	NULL
1.5	NULL
3.2	NULL
+	NULL
1.5	NULL
3.6	NULL
+	NULL
1.4	NULL
``	NULL
Intracellular	NULL
cytokines	NULL
were	NULL
detected	NULL
in	NULL
freshly	NULL
isolated	NULL
and	NULL
primed	NULL
effector	NULL
memory	NULL
T	NULL
cells	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

*	NULL
Statistically	NULL
significant	NULL
difference	NULL
compared	NULL
to	NULL
the	NULL
starting	NULL
population	NULL
within	NULL
the	NULL
same	NULL
group	NULL
(	NULL
paired	NULL
two-tailed	NULL
Student	NULL
's	NULL
£	NULL
test	NULL
)	NULL
.	NULL

©	NULL
Group	NULL
I	NULL
,	NULL
patients	NULL
with	NULL
anti-CD28	NULL
inducible	NULL
Th2	NULL
differentiation	NULL
;	NULL
group	NULL
II	NULL
,	NULL
patients	NULL
with	NULL
IL-4	NULL
dependent	NULL
Th2	NULL
differentiation	NULL
;	NULL
group	NULL
III	NULL
,	NULL
patients	NULL
with	NULL
Th2	NULL
differentiation	NULL
deficiency	NULL
.	NULL

anti-CD28-induced	NULL
Th2	NULL
cell	NULL
differentiation	NULL
in	NULL
all	NULL
healthy	NULL
individuals	NULL
and	NULL
resulted	NULL
in	NULL
an	NULL
additional	NULL
increase	NULL
in	NULL
the	NULL
number	NULL
of	NULL
Th2	NULL
cells	NULL
of	NULL
>	NULL
50	NULL
%	NULL
.	NULL

Impaired	NULL
Th2	NULL
memory	NULL
effector	NULL
cell	NULL
differentiation	NULL
in	NULL
RA	NULL
patients	NULL
Analysis	NULL
of	NULL
Th2	NULL
effector	NULL
cell	NULL
differentiation	NULL
in	NULL
RA	NULL
patients	NULL
revealed	NULL
striking	NULL
differences	NULL
compared	NULL
with	NULL
that	NULL
in	NULL
healthy	NULL
individuals	NULL
.	NULL

Statistical	NULL
examination	NULL
of	NULL
the	NULL
Th2	NULL
cell	NULL
differentiation	NULL
data	NULL
from	NULL
RA	NULL
patients	NULL
in	NULL
response	NULL
to	NULL
priming	NULL
under	NULL
Th2-inducing	NULL
conditions	NULL
suggested	NULL
that	NULL
the	NULL
data	NULL
were	NULL
not	NULL
normally	NULL
distributed	NULL
and	NULL
therefore	NULL
were	NULL
unlikely	NULL
to	NULL
be	NULL
derived	NULL
from	NULL
a	NULL
single	NULL
entity	NULL
but	NULL
,	NULL
fresh	NULL
memory	NULL
T	NULL
cells	NULL
rather	NULL
,	NULL
represented	NULL
different	NULL
cohorts	NULL
.	NULL

Patients	NULL
could	NULL
be	NULL
grouped	NULL
according	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
their	NULL
memory	NULL
T	NULL
cells	NULL
to	NULL
differentiate	NULL
into	NULL
Th2	NULL
effectors	NULL
under	NULL
optimal	NULL
Th2-inducing	NULL
conditions	NULL
.	NULL

In	NULL
nine	NULL
RA	NULL
patients	NULL
Th2	NULL
effectors	NULL
were	NULL
generated	NULL
by	NULL
priming	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
stimulation	NULL
in	NULL
a	NULL
way	NULL
comparable	NULL
to	NULL
that	NULL
in	NULL
healthy	NULL
controls	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
an	NULL
increase	NULL
of	NULL
Th2	NULL
cell	NULL
frequencies	NULL
of	NULL
at	NULL
least	NULL
50	NULL
%	NULL
was	NULL
initiated	NULL
by	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
in	NULL
these	NULL
patients	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

When	NULL
IL-4	NULL
was	NULL
added	NULL
during	NULL
priming	NULL
,	NULL
a	NULL
further	NULL
increase	NULL
in	NULL
the	NULL
Th2	NULL
cell	NULL
frequencies	NULL
within	NULL
the	NULL
primed	NULL
population	NULL
of	NULL
>	NULL
50	NULL
%	NULL
was	NULL
achieved	NULL
(	NULL
p	NULL
<	NULL
0.02	NULL
;	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
healthy	NULL
individuals	NULL
,	NULL
however	NULL
,	NULL
in	NULL
this	NULL
group	NULL
of	NULL
RA	NULL
patients	NULL
priming	NULL
with	NULL
anti	NULL
memory	NULL
effector	NULL
T	NULL
cells	NULL
after	NULL
priming	NULL
with	NULL
anti-CD28	NULL
anti-CD28	NULL
+	NULL
rIL-4	NULL
FIGURE	NULL
2	NULL
.	NULL

-	NULL
Generation	NULL
of	NULL
Th2	NULL
effectors	NULL
in	NULL
RA	NULL
patients	NULL
.	NULL

CD4*	NULL
memory	NULL
T	NULL
cells	NULL
were	NULL
iso-	NULL
lated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
from	NULL
RA	NULL
patients	NULL
.	NULL

Effector	NULL
cells	NULL
were	NULL
generated	NULL
by	NULL
priming	NULL
for	NULL
5	NULL
days	NULL
with	NULL
anti-CD28	NULL
without	NULL
ligation	NULL
of	NULL
the	NULL
TCR	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
rIL-4	NULL
.	NULL

Cytoplasmic	NULL
cytokines	NULL
were	NULL
detected	NULL
by	NULL
flow	NULL
cytometry	NULL
after	NULL
maximum	NULL
stimulation	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
numbers	NULL
indicate	NULL
the	NULL
percentage	NULL
of	NULL
cytokine-producing	NULL
cells	NULL
from	NULL
the	NULL
total	NULL
population	NULL
of	NULL
gated	NULL
viable	NULL
lymphocytes	NULL
.	NULL

Demonstrated	NULL
is	NULL
a	NULL
representative	NULL
cytokine	NULL
secretion	NULL
pattern	NULL
of	NULL
freshly	NULL
isolated	NULL
and	NULL
primed	NULL
memory	NULL
effector	NULL
T	NULL
cells	NULL
from	NULL
one	NULL
of	NULL
the	NULL
nine	NULL
RA	NULL
patients	NULL
in	NULL
whom	NULL
Th2	NULL
effectors	NULL
could	NULL
be	NULL
generated	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
that	NULL
in	NULL
healthy	NULL
controls	NULL
(	NULL
A	NULL
)	NULL
,	NULL
one	NULL
of	NULL
the	NULL
seven	NULL
RA	NULL
patients	NULL
in	NULL
whom	NULL
Th2	NULL
effector	NULL
gen	NULL
eration	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
IL-4	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
one	NULL
of	NULL
the	NULL
eight	NULL
RA	NULL
patients	NULL
with	NULL
defective	NULL
induction	NULL
of	NULL
Th2	NULL
effector	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
50	NULL
p	NULL
<	NULL
0.003	NULL
-	NULL
p	NULL
<	NULL
0.05	NULL
[	NULL
-I	NULL
40	NULL
30	NULL
20	NULL
frequency	NULL
of	NULL
cells	NULL
[	NULL
%	NULL
]	NULL
10	NULL
IFNy	NULL
``	NULL
°9	NULL
_	NULL
IFNy®®®	NULL
_	NULL
FNy	NULL
P°®	NULL
IL-2	NULL
POS	NULL
_	NULL
j_-2	NULL
POS	NULL
j_-2	NULL
neg	NULL
FIGURE	NULL
3	NULL
.	NULL

Altered	NULL
Th1	NULL
differentiation	NULL
in	NULL
RA	NULL
.	NULL

CD4*	NULL
memory	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
RA	NULL
patients	NULL
.	NULL

Th1	NULL
cells	NULL
were	NULL
generated	NULL
in	NULL
vitro	NULL
by	NULL
priming	NULL
for	NULL
5	NULL
days	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
and	NULL
a	NULL
mAb	NULL
to	NULL
CD28	NULL
.	NULL

After	NULL
rest	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
and	NULL
double	NULL
stained	NULL
with	NULL
mAb	NULL
to	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
,	NULL
and	NULL
cytoplasmic	NULL
cytokines	NULL
were	NULL
detected	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
the	NULL
frequencies	NULL
of	NULL
cells	NULL
producing	NULL
IL-2	NULL
and/or	NULL
IFN-y	NULL
from	NULL
healthy	NULL
controls	NULL
(	NULL
r	NULL
=	NULL
10	NULL
;	NULL
stippled	NULL
bars	NULL
)	NULL
or	NULL
RA	NULL
patients	NULL
(	NULL
r	NULL
=	NULL
24	NULL
;	NULL
solid	NULL
bars	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
data	NULL
was	NULL
performed	NULL
by	NULL
two-tailed	NULL
?	NULL

test	NULL
.	NULL

ns	NULL
,	NULL
Not	NULL
significant	NULL
.	NULL

CD28	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
immobilized	NULL
anti-CD3	NULL
also	NULL
significantly	NULL
increased	NULL
the	NULL
IL-4-producing	NULL
cells	NULL
(	NULL
p	NULL
<	NULL
0.05	NULL
;	NULL
Table	NULL
IIN	NULL
)	NULL
.	NULL

In	NULL
the	NULL
remaining	NULL
15	NULL
RA	NULL
patients	NULL
,	NULL
ThZ2	NULL
memory	NULL
effectors	NULL
could	NULL
not	NULL
be	NULL
generated	NULL
by	NULL
priming	NULL
of	NULL
CD4	NULL
*	NULL
memory	NULL
T	NULL
cells	NULL
with	NULL
anti-CD28	NULL
alone	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

There	NULL
was	NULL
a	NULL
significant	NULL
difference	NULL
in	NULL
the	NULL
frequencies	NULL
of	NULL
Th2	NULL
cells	NULL
after	NULL
priming	NULL
with	NULL
anti-CD28	NULL
between	NULL
this	NULL
group	NULL
of	NULL
patients	NULL
and	NULL
healthy	NULL
individuals	NULL
(	NULL
3.2	NULL
+	NULL
1.2	NULL
vs	NULL
5.7	NULL
+	NULL
1.3	NULL
;	NULL
p	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

Priming	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
IL-4	NULL
induced	NULL
Th2	NULL
cell	NULL
differentiation	NULL
in	NULL
7	NULL
of	NULL
these	NULL
15	NULL
patients	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

In	NULL
these	NULL
seven	NULL
patients	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
Th2	NULL
cells	NULL
was	NULL
achieved	NULL
after	NULL
culture	NULL
with	NULL
anti-CD28	NULL
and	NULL
rIL-4	NULL
compared	NULL
with	NULL
that	NULL
in	NULL
the	NULL
starting	NULL
population	NULL
(	NULL
p	NULL
<	NULL
0.005	NULL
;	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
however	NULL
,	NULL
in	NULL
eight	NULL
RA	NULL
patients	NULL
,	NULL
exogenous	NULL
IL-4	NULL
was	NULL
without	NULL
effect	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
generation	NULL
of	NULL
Th2	NULL
effectors	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

In	NULL
this	NULL
group	NULL
of	NULL
patients	NULL
,	NULL
the	NULL
Th2	NULL
cell	NULL
frequencies	NULL
were	NULL
3.0	NULL
+	NULL
1.1	NULL
%	NULL
in	NULL
freshly	NULL
isolated	NULL
cells	NULL
,	NULL
3.2	NULL
+	NULL
1.5	NULL
%	NULL
in	NULL
CD28-primed	NULL
effectors	NULL
,	NULL
and	NULL
3.6	NULL
+	NULL
1.4	NULL
%	NULL
in	NULL
effectors	NULL
that	NULL
were	NULL
primed	NULL
with	NULL
anti-CD28	NULL
and	NULL
IL-4	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
nine	NULL
patients	NULL
described	NULL
above	NULL
but	NULL
similar	NULL
to	NULL
healthy	NULL
individuals	NULL
,	NULL
Th2	NULL
cell	NULL
differentiation	NULL
was	NULL
not	NULL
observed	NULL
after	NULL
engagement	NULL
of	NULL
the	NULL
TCR	NULL
in	NULL
these	NULL
15	NULL
patients	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

495	NULL
Altered	NULL
Th1	NULL
cell	NULL
differentiation	NULL
in	NULL
RA	NULL
patients	NULL
TCR	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
Th1	NULL
cell	NULL
differentiation	NULL
(	NULL
31	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
Th1	NULL
cell	NULL
differentiation	NULL
of	NULL
RA	NULL
memory	NULL
T	NULL
cells	NULL
was	NULL
analyzed	NULL
after	NULL
priming	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
and	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
in	NULL
healthy	NULL
controls	NULL
.	NULL

A	NULL
significant	NULL
increase	NULL
in	NULL
the	NULL
numbers	NULL
of	NULL
IFN-y-producing	NULL
cells	NULL
occurred	NULL
after	NULL
priming	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
in	NULL
controls	NULL
and	NULL
patients	NULL
,	NULL
with	NULL
no	NULL
apparent	NULL
difference	NULL
between	NULL
the	NULL
groups	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
provide	NULL
a	NULL
more	NULL
detailed	NULL
analysis	NULL
of	NULL
the	NULL
cytokine	NULL
secretion	NULL
profile	NULL
of	NULL
individual	NULL
Th1	NULL
cells	NULL
,	NULL
freshly	NULL
isolated	NULL
CD4	NULL
*	NULL
memory	NULL
T	NULL
cells	NULL
and	NULL
effector	NULL
cells	NULL
were	NULL
double	NULL
stained	NULL
with	NULL
mAb	NULL
to	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
and	NULL
analyzed	NULL
for	NULL
the	NULL
distribution	NULL
of	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
double-producing	NULL
Th1	NULL
cells	NULL
and	NULL
more	NULL
specialized	NULL
IFN-y	NULL
single	NULL
producers	NULL
.	NULL

In	NULL
freshly	NULL
isolated	NULL
memory	NULL
T	NULL
cells	NULL
,	NULL
no	NULL
differences	NULL
were	NULL
detected	NULL
between	NULL
healthy	NULL
controls	NULL
and	NULL
RA	NULL
patients	NULL
or	NULL
the	NULL
patient	NULL
groups	NULL
in	NULL
which	NULL
Th2	NULL
cells	NULL
could	NULL
or	NULL
could	NULL
not	NULL
be	NULL
induced	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
after	NULL
priming	NULL
,	NULL
a	NULL
markedly	NULL
reduced	NULL
number	NULL
of	NULL
cells	NULL
that	NULL
produced	NULL
IL-2	NULL
only	NULL
and	NULL
a	NULL
significant	NULL
shift	NULL
in	NULL
the	NULL
balance	NULL
of	NULL
IFN-y/IL-2	NULL
double	NULL
producers	NULL
to	NULL
IFN-y	NULL
single-producing	NULL
Th1	NULL
cells	NULL
were	NULL
noted	NULL
in	NULL
RA	NULL
patients	NULL
compared	NULL
with	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Whereas	NULL
in	NULL
controls	NULL
,	NULL
18.6	NULL
+	NULL
4.6	NULL
%	NULL
of	NULL
the	NULL
primed	NULL
effector	NULL
cells	NULL
were	NULL
IL-2	NULL
single	NULL
producers	NULL
,	NULL
only	NULL
14.2	NULL
+	NULL
7.2	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
exclusively	NULL
contained	NULL
IL-2	NULL
.	NULL

Moreover	NULL
,	NULL
significantly	NULL
fewer	NULL
effector	NULL
cells	NULL
were	NULL
IFN-y/IL-2	NULL
double	NULL
producers	NULL
in	NULL
RA	NULL
patients	NULL
(	NULL
23.6	NULL
+	NULL
8.2	NULL
%	NULL
)	NULL
compared	NULL
with	NULL
those	NULL
in	NULL
healthy	NULL
individuals	NULL
(	NULL
33.1	NULL
+	NULL
7.0	NULL
%	NULL
;	NULL
p	NULL
<	NULL
0.003	NULL
)	NULL
.	NULL

Concomitantly	NULL
,	NULL
specialized	NULL
IFN-y	NULL
single	NULL
producers	NULL
were	NULL
found	NULL
more	NULL
frequently	NULL
among	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
than	NULL
in	NULL
healthy	NULL
individuals	NULL
(	NULL
29.0	NULL
+	NULL
11.5	NULL
%	NULL
vs	NULL
22.3	NULL
+	NULL
7.5	NULL
%	NULL
;	NULL
p	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

When	NULL
patients	NULL
with	NULL
impaired	NULL
Th2	NULL
cell	NULL
differentiation	NULL
were	NULL
analyzed	NULL
,	NULL
an	NULL
even	NULL
more	NULL
pronounced	NULL
shift	NULL
toward	NULL
specialized	NULL
Th1	NULL
cells	NULL
became	NULL
obvious	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
;	NULL
18.1	NULL
+	NULL
4.7	NULL
%	NULL
of	NULL
the	NULL
effector	NULL
cells	NULL
from	NULL
this	NULL
group	NULL
of	NULL
patients	NULL
were	NULL
positive	NULL
for	NULL
both	NULL
IFN-y	NULL
and	NULL
IL-2	NULL
,	NULL
and	NULL
32.1	NULL
+	NULL
12.4	NULL
%	NULL
were	NULL
specialized	NULL
IFN-y	NULL
single-producing	NULL
Th1	NULL
cells	NULL
.	NULL

Expression	NULL
and	NULL
phosphorylation	NULL
of	NULL
STAT6	NULL
in	NULL
RA	NULL
CD4*	NULL
T	NULL
cells	NULL
Exogenous	NULL
IL-4	NULL
had	NULL
no	NULL
effect	NULL
with	NULL
respect	NULL
to	NULL
Th2	NULL
cell	NULL
differentiation	NULL
in	NULL
eight	NULL
RA	NULL
patients	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
an	NULL
altered	NULL
expression	NULL
or	NULL
activation	NULL
of	NULL
STAT6	NULL
,	NULL
which	NULL
is	NULL
the	NULL
critical	NULL
signaling	NULL
molecule	NULL
downstream	NULL
of	NULL
the	NULL
IL-4R	NULL
(	NULL
44-46	NULL
)	NULL
,	NULL
might	NULL
underlie	NULL
the	NULL
impaired	NULL
cellular	NULL
response	NULL
to	NULL
IL-4	NULL
in	NULL
these	NULL
patients	NULL
,	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
them	NULL
and	NULL
from	NULL
controls	NULL
were	NULL
purified	NULL
and	NULL
stimulated	NULL
with	NULL
IL-4	NULL
.	NULL

STAT6	NULL
was	NULL
immunoprecipitated	NULL
and	NULL
probed	NULL
with	NULL
an	NULL
Ab	NULL
to	NULL
16.6	NULL
30.5	NULL
74	NULL
IL-2	NULL
29.1	NULL
9.4	NULL
19.7	NULL
IFN-y	NULL
FIGURE	NULL
4	NULL
.	NULL

Th	NULL
]	NULL
cytokines	NULL
in	NULL
ex	NULL
vivo	NULL
generated	NULL
memory	NULL
effector	NULL
cells	NULL
.	NULL

CD4*	NULL
memory	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
,	NULL
and	NULL
effector	NULL
cells	NULL
were	NULL
generated	NULL
by	NULL
priming	NULL
for	NULL
5	NULL
days	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
and	NULL
a	NULL
mAb	NULL
to	NULL
CD28	NULL
.	NULL

Cytoplasmic	NULL
cytokines	NULL
were	NULL
detected	NULL
by	NULL
flow	NULL
cytometry	NULL
after	NULL
maximum	NULL
stimulation	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
numbers	NULL
indicate	NULL
the	NULL
percentage	NULL
of	NULL
cytokine-producing	NULL
cells	NULL
from	NULL
the	NULL
total	NULL
population	NULL
of	NULL
gated	NULL
viable	NULL
cells	NULL
.	NULL

Demonstrated	NULL
is	NULL
a	NULL
representative	NULL
cytokine	NULL
secretion	NULL
pattern	NULL
of	NULL
one	NULL
of	NULL
the	NULL
10	NULL
healthy	NULL
controls	NULL
(	NULL
A	NULL
)	NULL
,	NULL
one	NULL
of	NULL
the	NULL
nine	NULL
RA	NULL
patients	NULL
in	NULL
whom	NULL
Th2	NULL
effectors	NULL
could	NULL
be	NULL
generated	NULL
in	NULL
a	NULL
manner	NULL
comparable	NULL
to	NULL
that	NULL
in	NULL
the	NULL
healthy	NULL
controls	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
one	NULL
of	NULL
the	NULL
15	NULL
RA	NULL
patients	NULL
with	NULL
impaired	NULL
anti-CD28-induced	NULL
Th2	NULL
effector	NULL
generation	NULL
(	NULL
C	NULL
)	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
496	NULL
healthy	NULL
control	NULL
patient	NULL
T	NULL
%	NULL
€	NULL
0	NULL
<	NULL
0	NULL
E	NULL
#	NULL
[	NULL
___	NULL
wee	NULL
___	NULL
|	NULL
.	NULL

1B	NULL
:	NULL
anti-pTyr	NULL
iB	NULL
:	NULL
anti-STAT6	NULL
FIGURE	NULL
5	NULL
.	NULL

Expression	NULL
and	NULL
IL-4-induced	NULL
phosphorylation	NULL
of	NULL
STAT6	NULL
.	NULL

Purified	NULL
CD4*	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
healthy	NULL
control	NULL
and	NULL
a	NULL
patient	NULL
with	NULL
impaired	NULL
Th2	NULL
cell	NULL
differentiation	NULL
(	NULL
group	NULL
III	NULL
)	NULL
were	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
rIL-4	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Immunoprecitation	NULL
of	NULL
STAT6	NULL
was	NULL
performed	NULL
on	NULL
whole	NULL
cell	NULL
lysates	NULL
followed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
Ab	NULL
to	NULL
phosphotyrosine	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
or	NULL
STAT6	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

IB	NULL
,	NULL
immunoblot	NULL
.	NULL

STAT6	NULL
or	NULL
a	NULL
mAb	NULL
to	NULL
phosphotyrosine	NULL
(	NULL
PY20	NULL
)	NULL
.	NULL

No	NULL
differences	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
STAT6	NULL
and	NULL
its	NULL
phosphorylation	NULL
after	NULL
activation	NULL
were	NULL
found	NULL
between	NULL
RA	NULL
patients	NULL
and	NULL
healthy	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Correlation	NULL
of	NULL
clinical	NULL
parameters	NULL
and	NULL
T	NULL
cell	NULL
differentiation	NULL
The	NULL
ex	NULL
vivo	NULL
T	NULL
cell	NULL
differentiation	NULL
data	NULL
were	NULL
compared	NULL
with	NULL
the	NULL
clinical	NULL
parameters	NULL
,	NULL
such	NULL
as	NULL
disease	NULL
duration	NULL
,	NULL
ESR	NULL
,	NULL
CRP	NULL
,	NULL
and	NULL
rheumatoid	NULL
factor	NULL
,	NULL
and	NULL
the	NULL
demographic	NULL
data	NULL
of	NULL
the	NULL
patients	NULL
,	NULL
such	NULL
as	NULL
age	NULL
,	NULL
sex	NULL
,	NULL
and	NULL
genetic	NULL
background	NULL
.	NULL

No	NULL
significant	NULL
correlation	NULL
to	NULL
any	NULL
of	NULL
these	NULL
parameters	NULL
was	NULL
found	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
,	NULL
however	NULL
,	NULL
that	NULL
the	NULL
frequency	NULL
of	NULL
patients	NULL
with	NULL
an	NULL
HLA-DR	NULL
allele	NULL
that	NULL
is	NULL
associated	NULL
with	NULL
aggressive	NULL
forms	NULL
of	NULL
RA	NULL
(	NULL
HLA-DRB1*O1	NULL
and	NULL
HLA-DRB1*04	NULL
)	NULL
was	NULL
0.67	NULL
(	NULL
10	NULL
of	NULL
15	NULL
)	NULL
in	NULL
the	NULL
patients	NULL
with	NULL
impaired	NULL
Th2	NULL
differentiation	NULL
compared	NULL
with	NULL
0.22	NULL
(	NULL
two	NULL
of	NULL
nine	NULL
)	NULL
in	NULL
the	NULL
group	NULL
of	NULL
patients	NULL
in	NULL
whom	NULL
Th2	NULL
effectors	NULL
could	NULL
be	NULL
induced	NULL
(	NULL
p	NULL
=	NULL
0.09	NULL
,	NULL
by	NULL
Fisher	NULL
's	NULL
exact	NULL
test	NULL
)	NULL
.	NULL

Discussion	NULL
Many	NULL
aspects	NULL
of	NULL
the	NULL
chronic	NULL
inflammation	NULL
in	NULL
RA	NULL
have	NULL
been	NULL
attributed	NULL
to	NULL
a	NULL
dominance	NULL
of	NULL
activated	NULL
Th1	NULL
effector	NULL
cells	NULL
(	NULL
17	NULL
,	NULL
20	NULL
,	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

As	NULL
disordered	NULL
differentiation	NULL
of	NULL
memory	NULL
effector	NULL
T	NULL
cells	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
development	NULL
of	NULL
the	NULL
characteristic	NULL
Th1	NULL
bias	NULL
in	NULL
RA	NULL
,	NULL
we	NULL
investigated	NULL
Th	NULL
effector	NULL
cell	NULL
differentiation	NULL
from	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
patients	NULL
with	NULL
early	NULL
,	NULL
untreated	NULL
active	NULL
RA	NULL
in	NULL
vitro	NULL
.	NULL

In	NULL
the	NULL
majority	NULL
of	NULL
patients	NULL
,	NULL
Th2	NULL
effector	NULL
cells	NULL
could	NULL
not	NULL
be	NULL
generated	NULL
under	NULL
priming	NULL
conditions	NULL
that	NULL
were	NULL
optimal	NULL
for	NULL
Th2	NULL
cell	NULL
differentiation	NULL
in	NULL
healthy	NULL
individuals	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
priming	NULL
with	NULL
anti-CD28	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
ligation	NULL
.	NULL

Th2	NULL
cell	NULL
differentiation	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
anti-CD28	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
ligation	NULL
in	NULL
all	NULL
of	NULL
10	NULL
healthy	NULL
individuals	NULL
from	NULL
the	NULL
current	NULL
study	NULL
in	NULL
a	NULL
rather	NULL
homogeneous	NULL
fashion	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
was	NULL
observed	NULL
in	NULL
a	NULL
group	NULL
of	NULL
healthy	NULL
volunteers	NULL
that	NULL
were	NULL
not	NULL
age	NULL
matched	NULL
with	NULL
the	NULL
study	NULL
population	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
induction	NULL
of	NULL
Th2	NULL
cell	NULL
differentiation	NULL
is	NULL
a	NULL
common	NULL
result	NULL
of	NULL
priming	NULL
of	NULL
memory	NULL
Th	NULL
cells	NULL
from	NULL
healthy	NULL
individuals	NULL
with	NULL
anti-CD28	NULL
.	NULL

The	NULL
intracellular	NULL
signals	NULL
induced	NULL
by	NULL
the	NULL
interactions	NULL
between	NULL
CD28	NULL
and	NULL
its	NULL
natural	NULL
ligands	NULL
CD80	NULL
and	NULL
CD86	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
not	NULL
only	NULL
complement	NULL
TCR-mediated	NULL
signals	NULL
to	NULL
allow	NULL
full	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
but	NULL
also	NULL
to	NULL
play	NULL
a	NULL
central	NULL
role	NULL
in	NULL
Th2	NULL
cell	NULL
differentiation	NULL
.	NULL

Whereas	NULL
immune	NULL
responses	NULL
driven	NULL
by	NULL
Thl1	NULL
cells	NULL
could	NULL
be	NULL
induced	NULL
in	NULL
CD28-deficient	NULL
mice	NULL
(	NULL
49	NULL
)	NULL
,	NULL
strong	NULL
(	NULL
co	NULL
)	NULL
stimu-latory	NULL
signals	NULL
through	NULL
CD28	NULL
were	NULL
required	NULL
to	NULL
induce	NULL
Th2	NULL
differentiation	NULL
(	NULL
34	NULL
,	NULL
35	NULL
,	NULL
50	NULL
)	NULL
.	NULL

The	NULL
proximal	NULL
and	NULL
distal	NULL
events	NULL
of	NULL
CD28	NULL
signaling	NULL
are	NULL
just	NULL
beginning	NULL
to	NULL
be	NULL
understood	NULL
.	NULL

Multiple	NULL
signaling	NULL
cascades	NULL
that	NULL
may	NULL
be	NULL
independent	NULL
of	NULL
or	NULL
dependent	NULL
on	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
activation	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
T	NULL
CELL	NULL
DIFFERENTIATION	NULL
IN	NULL
RHEUMATOID	NULL
ARTHRITIS	NULL
CD28	NULL
,	NULL
including	NULL
activation	NULL
of	NULL
phosphoinositide	NULL
3-kinase	NULL
,	NULL
extracel-lular	NULL
signal-regulating	NULL
kinases	NULL
1	NULL
and	NULL
2	NULL
,	NULL
stress-activated	NULL
protein	NULL
ki-nase/c-fun	NULL
amino	NULL
terminal	NULL
protein	NULL
kinase	NULL
,	NULL
and	NULL
mitogen	NULL
activation	NULL
protein	NULL
kinase	NULL
38	NULL
(	NULL
p38/HOG1	NULL
)	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

51	NULL
and	NULL
52	NULL
)	NULL
,	NULL
and	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
CD28-activated	NULL
signaling	NULL
cascades	NULL
regulate	NULL
several	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
cytokine	NULL
transcription	NULL
(	NULL
51	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
some	NULL
evidence	NULL
has	NULL
been	NULL
provided	NULL
demonstrating	NULL
that	NULL
signaling	NULL
through	NULL
CD28	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
ligation	NULL
is	NULL
sufficient	NULL
to	NULL
activate	NULL
resting	NULL
T	NULL
cells	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
cell	NULL
prolifer-ation	NULL
,	NULL
increase	NULL
of	NULL
intracellular	NULL
calcium	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
cytokine	NULL
gene	NULL
transcription	NULL
(	NULL
37	NULL
,	NULL
53	NULL
)	NULL
.	NULL

The	NULL
precise	NULL
mechanisms	NULL
,	NULL
however	NULL
,	NULL
that	NULL
contribute	NULL
to	NULL
anti-CD28-induced	NULL
Th2	NULL
cell	NULL
differentiation	NULL
remain	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

Analysis	NULL
of	NULL
freshly	NULL
isolated	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
with	NULL
flow	NULL
cytometry	NULL
after	NULL
staining	NULL
with	NULL
mAbs	NULL
to	NULL
CD28	NULL
revealed	NULL
no	NULL
differences	NULL
in	NULL
the	NULL
density	NULL
of	NULL
CD28	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
cells	NULL
from	NULL
healthy	NULL
individuals	NULL
and	NULL
patients	NULL
or	NULL
between	NULL
individual	NULL
patient	NULL
groups	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
confirming	NULL
previous	NULL
reports	NULL
in	NULL
which	NULL
no	NULL
abnormalities	NULL
in	NULL
surface	NULL
CD28	NULL
were	NULL
detected	NULL
in	NULL
RA	NULL
patients	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
CD28	NULL
signaling	NULL
in	NULL
CD4*	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
RA	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
functionally	NULL
intact	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
proliferative	NULL
responses	NULL
to	NULL
anti-CD3/anti-CD28-induced	NULL
activation	NULL
(	NULL
55	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
these	NULL
data	NULL
,	NULL
no	NULL
differences	NULL
between	NULL
RA	NULL
patients	NULL
and	NULL
healthy	NULL
controls	NULL
in	NULL
the	NULL
proliferation	NULL
of	NULL
memory	NULL
cells	NULL
and	NULL
the	NULL
viability	NULL
of	NULL
recovered	NULL
effector	NULL
cells	NULL
were	NULL
observed	NULL
in	NULL
the	NULL
current	NULL
study	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
alone	NULL
or	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
in	NULL
combination	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
despite	NULL
similar	NULL
proliferative	NULL
responses	NULL
and	NULL
comparable	NULL
densities	NULL
of	NULL
surface	NULL
CD28	NULL
,	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
majority	NULL
of	NULL
RA	NULL
patients	NULL
failed	NULL
to	NULL
differentiate	NULL
into	NULL
IL-4-producing	NULL
Th2	NULL
effector	NULL
cells	NULL
after	NULL
CD28	NULL
stimulation	NULL
.	NULL

Thus	NULL
,	NULL
CD28-mediated	NULL
signals	NULL
in	NULL
those	NULL
patients	NULL
were	NULL
apparently	NULL
intact	NULL
with	NULL
respect	NULL
to	NULL
proliferation	NULL
of	NULL
memory	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
were	NULL
impaired	NULL
with	NULL
regard	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
Th2	NULL
differentiation	NULL
.	NULL

An	NULL
indication	NULL
of	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
defect	NULL
in	NULL
CD28	NULL
signaling	NULL
,	NULL
however	NULL
,	NULL
might	NULL
derive	NULL
from	NULL
the	NULL
observation	NULL
that	NULL
in	NULL
seven	NULL
of	NULL
the	NULL
15	NULL
patients	NULL
with	NULL
impaired	NULL
Th2	NULL
cell	NULL
differentiation	NULL
,	NULL
priming	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
IL-4	NULL
could	NULL
overcome	NULL
the	NULL
failure	NULL
to	NULL
induce	NULL
Th2	NULL
cell	NULL
differentiation	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
healthy	NULL
individuals	NULL
that	NULL
Th2	NULL
effector	NULL
generation	NULL
from	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
is	NULL
IL-4	NULL
dependent	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
can	NULL
be	NULL
surmised	NULL
that	NULL
in	NULL
those	NULL
patients	NULL
,	NULL
IL-4R-mediated	NULL
signals	NULL
triggered	NULL
by	NULL
exogenous	NULL
IL-4	NULL
are	NULL
required	NULL
to	NULL
supplement	NULL
CD28	NULL
signals	NULL
for	NULL
the	NULL
initiation	NULL
of	NULL
Th2	NULL
cell	NULL
differentiation	NULL
.	NULL

Strikingly	NULL
,	NULL
however	NULL
,	NULL
in	NULL
the	NULL
remaining	NULL
eight	NULL
of	NULL
the	NULL
15	NULL
patients	NULL
,	NULL
even	NULL
large	NULL
concentrations	NULL
of	NULL
exogenous	NULL
IL-4	NULL
did	NULL
not	NULL
yield	NULL
Th2	NULL
effectors	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
in	NULL
RA	NULL
patients	NULL
with	NULL
long	NULL
standing	NULL
disease	NULL
,	NULL
T	NULL
cells	NULL
derived	NULL
from	NULL
the	NULL
synovial	NULL
tissue	NULL
predominantly	NULL
produced	NULL
IL-2	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
IL-10	NULL
(	NULL
11	NULL
,	NULL
16	NULL
,	NULL
18-22	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
those	NULL
cells	NULL
were	NULL
also	NULL
resistant	NULL
to	NULL
modulation	NULL
of	NULL
their	NULL
phenotype	NULL
after	NULL
stimulation	NULL
under	NULL
Th2-inducing	NULL
conditions	NULL
(	NULL
57	NULL
)	NULL
.	NULL

However	NULL
,	NULL
those	NULL
cells	NULL
might	NULL
have	NULL
been	NULL
primed	NULL
and	NULL
activated	NULL
in	NULL
vivo	NULL
and	NULL
therefore	NULL
might	NULL
have	NULL
lost	NULL
the	NULL
flexibility	NULL
of	NULL
functional	NULL
modulation	NULL
,	NULL
as	NULL
has	NULL
been	NULL
demonstrated	NULL
for	NULL
repeatedly	NULL
activated	NULL
T	NULL
cell	NULL
lines	NULL
(	NULL
40	NULL
)	NULL
.	NULL

In	NULL
the	NULL
current	NULL
study	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
patients	NULL
with	NULL
early	NULL
RA	NULL
were	NULL
analyzed	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
patients	NULL
had	NULL
symptoms	NULL
of	NULL
the	NULL
disease	NULL
for	NULL
as	NULL
little	NULL
as	NULL
6	NULL
wk	NULL
,	NULL
which	NULL
makes	NULL
it	NULL
unlikely	NULL
that	NULL
the	NULL
impairment	NULL
of	NULL
Th2	NULL
differentiation	NULL
is	NULL
secondary	NULL
to	NULL
long	NULL
standing	NULL
inflammation	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
finding	NULL
that	NULL
the	NULL
cells	NULL
from	NULL
these	NULL
patients	NULL
were	NULL
unable	NULL
to	NULL
generate	NULL
Th2	NULL
effector	NULL
cells	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
IL-4	NULL
strongly	NULL
suggests	NULL
that	NULL
a	NULL
disordered	NULL
potential	NULL
for	NULL
memory	NULL
cell	NULL
differentiation	NULL
contributes	NULL
not	NULL
only	NULL
to	NULL
the	NULL
perpetuation	NULL
but	NULL
,	NULL
more	NULL
importantly	NULL
,	NULL
to	NULL
the	NULL
initiation	NULL
of	NULL
the	NULL
unresolved	NULL
Th1-mediated	NULL
inflammation	NULL
in	NULL
some	NULL
patients	NULL
with	NULL
RA	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
The	NULL
data	NULL
imply	NULL
that	NULL
in	NULL
some	NULL
RA	NULL
patients	NULL
memory	NULL
T	NULL
cells	NULL
not	NULL
only	NULL
failed	NULL
to	NULL
initiate	NULL
Th2	NULL
effector	NULL
cell	NULL
differentiation	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
,	NULL
but	NULL
also	NULL
expressed	NULL
a	NULL
reduced	NULL
cellular	NULL
response	NULL
to	NULL
IL-4	NULL
.	NULL

Several	NULL
molecules	NULL
have	NULL
been	NULL
identified	NULL
that	NULL
are	NULL
involved	NULL
in	NULL
transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
IL-4R	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
binding	NULL
of	NULL
IL-4	NULL
to	NULL
its	NULL
receptor	NULL
initiates	NULL
phosphorylation	NULL
of	NULL
JAK3	NULL
and	NULL
JAK	NULL
1	NULL
that	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
phosphorylate	NULL
STAT6	NULL
,	NULL
which	NULL
exists	NULL
in	NULL
a	NULL
latent	NULL
form	NULL
in	NULL
the	NULL
cytoplasm	NULL
(	NULL
46	NULL
,	NULL
58	NULL
,	NULL
59	NULL
)	NULL
.	NULL

Whereas	NULL
JAK	NULL
1	NULL
and	NULL
JAK3	NULL
are	NULL
activated	NULL
by	NULL
several	NULL
cytokines	NULL
,	NULL
STAT6	NULL
confers	NULL
spec-ificity	NULL
to	NULL
IL-4R-mediated	NULL
signals	NULL
and	NULL
is	NULL
the	NULL
only	NULL
presently	NULL
known	NULL
STAT	NULL
protein	NULL
that	NULL
is	NULL
activated	NULL
in	NULL
response	NULL
to	NULL
IL-4	NULL
(	NULL
58	NULL
,	NULL
59	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
conclusively	NULL
shown	NULL
that	NULL
STAT6	NULL
is	NULL
required	NULL
for	NULL
IL-4	NULL
responses	NULL
and	NULL
for	NULL
the	NULL
development	NULL
of	NULL
Th2	NULL
cells	NULL
(	NULL
44-46	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
developing	NULL
Th1	NULL
cells	NULL
express	NULL
a	NULL
reduced	NULL
phosphorylation	NULL
of	NULL
JAK3	NULL
and	NULL
subsequently	NULL
of	NULL
STAT6	NULL
,	NULL
and	NULL
it	NULL
has	NULL
been	NULL
speculated	NULL
that	NULL
this	NULL
might	NULL
be	NULL
a	NULL
mechanism	NULL
of	NULL
phenotype	NULL
determination	NULL
(	NULL
60	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
an	NULL
alteration	NULL
in	NULL
the	NULL
expression	NULL
and/or	NULL
activation	NULL
of	NULL
STAT6	NULL
in	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
with	NULL
impaired	NULL
Th2	NULL
differentiation	NULL
might	NULL
contribute	NULL
to	NULL
reduced	NULL
IL-4	NULL
responsiveness	NULL
.	NULL

However	NULL
,	NULL
no	NULL
differences	NULL
were	NULL
detected	NULL
in	NULL
STAT6	NULL
expression	NULL
and	NULL
phosphorylation	NULL
after	NULL
IL-4-induced	NULL
activation	NULL
between	NULL
patients	NULL
with	NULL
impaired	NULL
Th2	NULL
differentiation	NULL
and	NULL
controls	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
precise	NULL
molecular	NULL
mechanisms	NULL
of	NULL
reduced	NULL
functional	NULL
cellular	NULL
responsiveness	NULL
to	NULL
IL-4	NULL
in	NULL
these	NULL
RA	NULL
patients	NULL
still	NULL
must	NULL
be	NULL
identified	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Th2	NULL
cell	NULL
differentiation	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
priming	NULL
with	NULL
anti-CD28	NULL
in	NULL
other	NULL
patients	NULL
from	NULL
the	NULL
current	NULL
study	NULL
and	NULL
could	NULL
be	NULL
further	NULL
enhanced	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
exogenous	NULL
IL-4	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
Th2	NULL
cell	NULL
frequencies	NULL
in	NULL
CD28-primed	NULL
populations	NULL
is	NULL
not	NULL
simply	NULL
caused	NULL
by	NULL
preferential	NULL
survival	NULL
of	NULL
a	NULL
subset	NULL
of	NULL
T	NULL
cells	NULL
but	NULL
clearly	NULL
results	NULL
from	NULL
expansion	NULL
of	NULL
early	NULL
uncommitted	NULL
CD27*	NULL
T	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
.	NULL

In	NULL
these	NULL
patients	NULL
,	NULL
therefore	NULL
,	NULL
CD28-mediated	NULL
signaling	NULL
appeared	NULL
to	NULL
be	NULL
intact	NULL
in	NULL
resting	NULL
,	NULL
uncommitted	NULL
memory	NULL
T	NULL
cells	NULL
with	NULL
regard	NULL
to	NULL
proliferation	NULL
and	NULL
the	NULL
initiation	NULL
of	NULL
differentiation	NULL
.	NULL

Furthermore	NULL
,	NULL
cellular	NULL
responsiveness	NULL
to	NULL
IL-4	NULL
in	NULL
these	NULL
patients	NULL
was	NULL
comparable	NULL
with	NULL
that	NULL
in	NULL
normal	NULL
controls	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
in	NULL
these	NULL
patients	NULL
even	NULL
higher	NULL
numbers	NULL
of	NULL
Th2	NULL
cells	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
priming	NULL
with	NULL
anti-CD28	NULL
or	NULL
anti-CD28	NULL
and	NULL
rIL-4	NULL
compared	NULL
with	NULL
healthy	NULL
controls	NULL
,	NULL
and	NULL
that	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
controls	NULL
,	NULL
Th2	NULL
cells	NULL
could	NULL
also	NULL
be	NULL
generated	NULL
when	NULL
the	NULL
TCR	NULL
was	NULL
stimulated	NULL
during	NULL
priming	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

These	NULL
data	NULL
imply	NULL
that	NULL
the	NULL
cells	NULL
from	NULL
these	NULL
patients	NULL
were	NULL
more	NULL
sensitive	NULL
to	NULL
Th2-inducing	NULL
priming	NULL
conditions	NULL
.	NULL

It	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
the	NULL
consequences	NULL
of	NULL
increased	NULL
Th2	NULL
generation	NULL
.	NULL

It	NULL
was	NULL
previously	NULL
reasoned	NULL
that	NULL
RA	NULL
is	NULL
a	NULL
heterogeneous	NULL
entity	NULL
with	NULL
distinct	NULL
histologically	NULL
defined	NULL
phenotypes	NULL
and	NULL
that	NULL
several	NULL
pathologic	NULL
mechanisms	NULL
may	NULL
cause	NULL
an	NULL
RA-like	NULL
syndrome	NULL
(	NULL
61	NULL
,	NULL
62	NULL
)	NULL
.	NULL

In	NULL
those	NULL
studies	NULL
variants	NULL
of	NULL
RA	NULL
have	NULL
been	NULL
postulated	NULL
based	NULL
upon	NULL
different	NULL
cytokine	NULL
secretion	NULL
patterns	NULL
in	NULL
tissue	NULL
sections	NULL
of	NULL
synovial	NULL
biopsies	NULL
that	NULL
could	NULL
be	NULL
correlated	NULL
with	NULL
the	NULL
clinical	NULL
progress	NULL
of	NULL
the	NULL
disease	NULL
in	NULL
the	NULL
patients	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
might	NULL
be	NULL
speculated	NULL
that	NULL
the	NULL
RA	NULL
patients	NULL
with	NULL
increased	NULL
Th2	NULL
differentiation	NULL
might	NULL
suffer	NULL
from	NULL
a	NULL
more	NULL
self-limited	NULL
diseas-e	NULL
(	NULL
s	NULL
)	NULL
,	NULL
related	NULL
clinically	NULL
to	NULL
RA	NULL
but	NULL
not	NULL
pathogenetically	NULL
.	NULL

Follow-up	NULL
evaluation	NULL
of	NULL
these	NULL
patients	NULL
should	NULL
provide	NULL
information	NULL
to	NULL
test	NULL
this	NULL
hypothesis	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
it	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
only	NULL
two	NULL
of	NULL
those	NULL
nine	NULL
patients	NULL
were	NULL
positive	NULL
for	NULL
an	NULL
HLA-DR	NULL
allele	NULL
that	NULL
is	NULL
associated	NULL
with	NULL
aggressive	NULL
forms	NULL
of	NULL
the	NULL
disease	NULL
(	NULL
HLA-DRB1*O01	NULL
or	NULL
HLA-DRB1*04	NULL
)	NULL
compared	NULL
with	NULL
10	NULL
of	NULL
the	NULL
15	NULL
patients	NULL
with	NULL
impaired	NULL
Th2	NULL
differentiation	NULL
.	NULL

Although	NULL
the	NULL
ability	NULL
of	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
to	NULL
generate	NULL
Th2	NULL
effectors	NULL
allowed	NULL
a	NULL
clear	NULL
separation	NULL
of	NULL
the	NULL
patients	NULL
,	NULL
no	NULL
correlations	NULL
with	NULL
clinical	NULL
and	NULL
demographic	NULL
data	NULL
were	NULL
detected	NULL
.	NULL

However	NULL
,	NULL
it	NULL
should	NULL
be	NULL
emphasized	NULL
that	NULL
the	NULL
patients	NULL
from	NULL
the	NULL
current	NULL
study	NULL
were	NULL
required	NULL
to	NULL
have	NULL
early	NULL
disease	NULL
with	NULL
symptoms	NULL
for	NULL
6	NULL
wk	NULL
to	NULL
12	NULL
mo	NULL
and	NULL
no	NULL
previous	NULL
treatment	NULL
with	NULL
corticosteroids	NULL
and	NULL
497	NULL
DMARDs	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
patients	NULL
were	NULL
analyzed	NULL
upon	NULL
their	NULL
first	NULL
visit	NULL
to	NULL
a	NULL
rheumatologist	NULL
when	NULL
disease	NULL
might	NULL
not	NULL
have	NULL
proceeded	NULL
far	NULL
enough	NULL
to	NULL
manifest	NULL
clear	NULL
differences	NULL
between	NULL
individual	NULL
patients	NULL
.	NULL

Nevertheless	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
from	NULL
the	NULL
data	NULL
that	NULL
patients	NULL
with	NULL
similar	NULL
clinical	NULL
symptoms	NULL
might	NULL
have	NULL
different	NULL
cellular	NULL
pathogenetic	NULL
mechanisms	NULL
.	NULL

The	NULL
cytokine	NULL
secretion	NULL
profiles	NULL
of	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
RA	NULL
patients	NULL
and	NULL
healthy	NULL
individuals	NULL
stimulated	NULL
immediately	NULL
after	NULL
purification	NULL
were	NULL
comparable	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
frequencies	NULL
of	NULL
cells	NULL
producing	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
or	NULL
IFN-y	NULL
.	NULL

As	NULL
Th2	NULL
differentiation	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
IL-4	NULL
and	NULL
could	NULL
not	NULL
be	NULL
induced	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
cells	NULL
that	NULL
were	NULL
able	NULL
to	NULL
produce	NULL
IL-4	NULL
(	NULL
37	NULL
)	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
memory	NULL
cells	NULL
capable	NULL
of	NULL
producing	NULL
IL-4	NULL
would	NULL
have	NULL
provided	NULL
a	NULL
simple	NULL
explanation	NULL
for	NULL
the	NULL
observed	NULL
differences	NULL
in	NULL
Th2	NULL
cell	NULL
generation	NULL
.	NULL

However	NULL
,	NULL
as	NULL
the	NULL
frequencies	NULL
of	NULL
cells	NULL
producing	NULL
IL-4	NULL
after	NULL
stimulation	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
were	NULL
indistinguishable	NULL
between	NULL
RA	NULL
patients	NULL
and	NULL
healthy	NULL
individuals	NULL
and	NULL
among	NULL
the	NULL
different	NULL
patient	NULL
groups	NULL
,	NULL
impaired	NULL
Th2	NULL
cell	NULL
differentiation	NULL
could	NULL
not	NULL
simply	NULL
be	NULL
attributed	NULL
to	NULL
a	NULL
lack	NULL
of	NULL
cells	NULL
capable	NULL
of	NULL
secreting	NULL
IL-4	NULL
but	NULL
,	NULL
rather	NULL
,	NULL
is	NULL
more	NULL
likely	NULL
to	NULL
be	NULL
related	NULL
to	NULL
an	NULL
impairment	NULL
of	NULL
the	NULL
cells	NULL
'	NULL
capacity	NULL
to	NULL
respond	NULL
appropriately	NULL
to	NULL
CD28	NULL
and/or	NULL
IL-4	NULL
signaling	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
controls	NULL
and	NULL
patients	NULL
were	NULL
similar	NULL
with	NULL
respect	NULL
to	NULL
their	NULL
cytokine	NULL
secretion	NULL
patterns	NULL
also	NULL
indicates	NULL
that	NULL
in	NULL
RA	NULL
patients	NULL
Th	NULL
cell	NULL
differentiation	NULL
was	NULL
apparently	NULL
normal	NULL
to	NULL
some	NULL
extent	NULL
before	NULL
the	NULL
disease	NULL
had	NULL
become	NULL
manifest	NULL
.	NULL

Presumably	NULL
,	NULL
the	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
patients	NULL
were	NULL
generated	NULL
in	NULL
response	NULL
to	NULL
some	NULL
antecedent	NULL
antigenic	NULL
exposure	NULL
.	NULL

Clini-cally	NULL
,	NULL
the	NULL
immune	NULL
responses	NULL
of	NULL
RA	NULL
patients	NULL
appear	NULL
to	NULL
be	NULL
normal	NULL
before	NULL
the	NULL
onset	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

It	NULL
might	NULL
be	NULL
speculated	NULL
,	NULL
therefore	NULL
,	NULL
that	NULL
Th	NULL
cell	NULL
differentiation	NULL
is	NULL
not	NULL
significantly	NULL
altered	NULL
in	NULL
RA	NULL
patients	NULL
before	NULL
the	NULL
initiation	NULL
of	NULL
the	NULL
disease	NULL
,	NULL
which	NULL
could	NULL
indicate	NULL
that	NULL
the	NULL
resting	NULL
memory	NULL
T	NULL
cell	NULL
population	NULL
from	NULL
patients	NULL
with	NULL
early	NULL
RA	NULL
were	NULL
generated	NULL
in	NULL
response	NULL
to	NULL
peptides	NULL
that	NULL
were	NULL
presented	NULL
by	NULL
non-RA-associated	NULL
MHC	NULL
class	NULL
II	NULL
alleles	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
data	NULL
might	NULL
indicate	NULL
that	NULL
the	NULL
T	NULL
cell	NULL
differentiation	NULL
defect	NULL
in	NULL
RA	NULL
is	NULL
acquired	NULL
rather	NULL
than	NULL
genetic	NULL
,	NULL
which	NULL
might	NULL
have	NULL
substantial	NULL
implications	NULL
for	NULL
the	NULL
pathogenesis	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Supportive	NULL
of	NULL
recent	NULL
suggestions	NULL
of	NULL
a	NULL
Th1-dominated	NULL
immune	NULL
response	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
RA	NULL
(	NULL
17	NULL
,	NULL
20	NULL
,	NULL
47	NULL
,	NULL
48	NULL
)	NULL
,	NULL
an	NULL
alteration	NULL
in	NULL
the	NULL
differentiation	NULL
of	NULL
resting	NULL
memory	NULL
T	NULL
cells	NULL
into	NULL
Th1	NULL
effectors	NULL
was	NULL
obvious	NULL
in	NULL
all	NULL
patients	NULL
.	NULL

Whereas	NULL
the	NULL
frequencies	NULL
of	NULL
cells	NULL
producing	NULL
IFN-y	NULL
were	NULL
similar	NULL
in	NULL
patients	NULL
and	NULL
controls	NULL
after	NULL
priming	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
,	NULL
a	NULL
marked	NULL
decrease	NULL
in	NULL
IL-2-producing	NULL
cells	NULL
and	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
specialized	NULL
Thl	NULL
cells	NULL
that	NULL
produced	NULL
IFN-y	NULL
but	NULL
not	NULL
IL-2	NULL
were	NULL
evident	NULL
in	NULL
RA	NULL
patients	NULL
.	NULL

An	NULL
even	NULL
more	NULL
pronounced	NULL
differentiation	NULL
into	NULL
specialized	NULL
Th1	NULL
cells	NULL
producing	NULL
only	NULL
IFN-y	NULL
was	NULL
noted	NULL
in	NULL
patients	NULL
in	NULL
whom	NULL
Th2	NULL
cells	NULL
could	NULL
not	NULL
be	NULL
induced	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
an	NULL
alteration	NULL
of	NULL
Th1	NULL
cell	NULL
differentiation	NULL
is	NULL
a	NULL
common	NULL
finding	NULL
in	NULL
RA	NULL
,	NULL
but	NULL
is	NULL
enhanced	NULL
in	NULL
patients	NULL
in	NULL
whom	NULL
a	NULL
concomitant	NULL
Th2	NULL
differentiation	NULL
defect	NULL
could	NULL
be	NULL
detected	NULL
.	NULL

In	NULL
combination	NULL
,	NULL
these	NULL
functional	NULL
abnormalities	NULL
might	NULL
result	NULL
in	NULL
a	NULL
marked	NULL
shift	NULL
of	NULL
the	NULL
Th1/Th2	NULL
balance	NULL
in	NULL
activated	NULL
effector	NULL
cells	NULL
of	NULL
these	NULL
individuals	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
we	NULL
have	NULL
provided	NULL
evidence	NULL
that	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
early	NULL
RA	NULL
express	NULL
an	NULL
altered	NULL
ability	NULL
to	NULL
differentiate	NULL
into	NULL
Th	NULL
effectors	NULL
.	NULL

RA	NULL
patients	NULL
could	NULL
be	NULL
grouped	NULL
according	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
their	NULL
memory	NULL
T	NULL
cells	NULL
to	NULL
differentiate	NULL
into	NULL
Th2	NULL
effectors	NULL
.	NULL

Whereas	NULL
in	NULL
some	NULL
patients	NULL
Th2	NULL
differentiation	NULL
could	NULL
be	NULL
in-duced	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
patients	NULL
were	NULL
identified	NULL
to	NULL
have	NULL
a	NULL
decreased	NULL
ability	NULL
to	NULL
generate	NULL
Th2	NULL
effectors	NULL
in	NULL
response	NULL
to	NULL
CD28-mediated	NULL
signals	NULL
,	NULL
and	NULL
some	NULL
of	NULL
them	NULL
also	NULL
failed	NULL
to	NULL
respond	NULL
to	NULL
IL-4	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
a	NULL
reduced	NULL
functional	NULL
responsiveness	NULL
to	NULL
Th2-inducing	NULL
signals	NULL
,	NULL
in	NULL
particular	NULL
CD28	NULL
engagement	NULL
and	NULL
IL-4	NULL
,	NULL
in	NULL
patients	NULL
with	NULL
RA	NULL
.	NULL

Moreover	NULL
,	NULL
increased	NULL
generation	NULL
of	NULL
Th1	NULL
cells	NULL
specialized	NULL
in	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
498	NULL
secreting	NULL
IFN-y	NULL
,	NULL
but	NULL
not	NULL
IL-2	NULL
,	NULL
was	NULL
obvious	NULL
in	NULL
all	NULL
patients	NULL
.	NULL

Altered	NULL
Th1	NULL
cell	NULL
differentiation	NULL
and	NULL
impaired	NULL
generation	NULL
of	NULL
Th2	NULL
cells	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
characteristic	NULL
Th1-dominated	NULL
inflammation	NULL
in	NULL
RA	NULL
.	NULL

These	NULL
results	NULL
imply	NULL
that	NULL
abnormalities	NULL
in	NULL
the	NULL
potential	NULL
of	NULL
memory	NULL
T	NULL
cells	NULL
to	NULL
differentiate	NULL
into	NULL
polarized	NULL
effector	NULL
cells	NULL
may	NULL
occur	NULL
early	NULL
in	NULL
the	NULL
course	NULL
of	NULL
RA	NULL
and	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
subsequent	NULL
evolution	NULL
of	NULL
chronic	NULL
inflammation	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Sabine	NULL
D.	NULL
Jorg	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

The	NULL
authors	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
Riidiger	NULL
de	NULL
la	NULL
Camp	NULL
and	NULL
Dr.	NULL
Florian	NULL
Schuch	NULL
for	NULL
providing	NULL
some	NULL
of	NULL
the	NULL
patients	NULL
,	NULL
and	NULL
to	NULL
Dr.	NULL
Ralf	NULL
Wafmuth	NULL
for	NULL
HLA	NULL
typing	NULL
of	NULL
the	NULL
patients	NULL
.	NULL

References	NULL
1	NULL
.	NULL

2	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

Van	NULL
Boxel	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Paget	NULL
.	NULL

1975	NULL
.	NULL

Predominantly	NULL
T-cell	NULL
infiltrate	NULL
in	NULL
theu-matoid	NULL
synovial	NULL
membranes	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

293:517	NULL
.	NULL

Sewell	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
and	NULL
D.	NULL
E.	NULL
Trentham	NULL
.	NULL

1993	NULL
.	NULL

Pathogenesis	NULL
of	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Lancet	NULL
341:283.	NULL
.	NULL

Schulze-Koops	NULL
,	NULL
H.	NULL
,	NULL
L.	NULL
S.	NULL
Davis	NULL
,	NULL
T.	NULL
P.	NULL
Haverty	NULL
,	NULL
M.	NULL
C.	NULL
Wacholtz	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1998	NULL
.	NULL

Reduction	NULL
of	NULL
Th1	NULL
cell	NULL
activity	NULL
in	NULL
the	NULL
peripheral	NULL
circulation	NULL
of	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
after	NULL
treatment	NULL
with	NULL
a	NULL
non-depleting	NULL
humanized	NULL
monoclonal	NULL
antibody	NULL
to	NULL
CD4	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

25:2065.	NULL
.	NULL

Janossy	NULL
,	NULL
G.	NULL
,	NULL
G.	NULL
Panayi	NULL
,	NULL
O.	NULL
Duke	NULL
,	NULL
M.	NULL
Bofill	NULL
,	NULL
L.	NULL
W.	NULL
Poulter	NULL
,	NULL
and	NULL
G.	NULL
Goldstein	NULL
.	NULL

1981	NULL
.	NULL

Rheumatoid	NULL
arthritis	NULL
:	NULL
a	NULL
disease	NULL
of	NULL
T-lymphocyte/macrophage	NULL
immunoregu-lation	NULL
.	NULL

Lancet	NULL
2:839.	NULL
.	NULL

Sanders	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
M.	NULL
W.	NULL
Makgoba	NULL
,	NULL
and	NULL
S.	NULL
Shaw	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
naive	NULL
and	NULL
memory	NULL
T	NULL
cells	NULL
:	NULL
reinterpretation	NULL
of	NULL
helper-inducer	NULL
and	NULL
suppressor-inducer	NULL
subsets	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
9:195.	NULL
.	NULL

Seder	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
W.	NULL
E.	NULL
Paul	NULL
.	NULL

1994	NULL
.	NULL

Acquisition	NULL
of	NULL
lymphokine-producing	NULL
phe-	NULL
notype	NULL
by	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12:635.	NULL
.	NULL

Mosmann	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
H.	NULL
Cherwinski	NULL
,	NULL
M.	NULL
W.	NULL
Bond	NULL
,	NULL
M.	NULL
A.	NULL
Giedlin	NULL
,	NULL
and	NULL
R.	NULL
L.	NULL
Coffman	NULL
.	NULL

1986	NULL
.	NULL

Two	NULL
types	NULL
of	NULL
murine	NULL
helper	NULL
T	NULL
cell	NULL
clone	NULL
.	NULL

I	NULL
.	NULL

Definition	NULL
according	NULL
to	NULL
profiles	NULL
of	NULL
lymphokine	NULL
activities	NULL
and	NULL
secreted	NULL
proteins	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

136:2348.	NULL
.	NULL

Del	NULL
Prete	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
M.	NULL
De	NULL
Carli	NULL
,	NULL
M.	NULL
Ricci	NULL
,	NULL
and	NULL
S.	NULL
Romagnani	NULL
.	NULL

1991	NULL
.	NULL

Helper	NULL
activity	NULL
for	NULL
immunoglobulin	NULL
synthesis	NULL
of	NULL
T	NULL
helper	NULL
type	NULL
1	NULL
(	NULL
Th1	NULL
)	NULL
and	NULL
Th2	NULL
human	NULL
T	NULL
cell	NULL
clones	NULL
:	NULL
the	NULL
help	NULL
of	NULL
Th1	NULL
clones	NULL
is	NULL
limited	NULL
by	NULL
their	NULL
cytolytic	NULL
capacity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

174:809.	NULL
.	NULL

Groux	NULL
,	NULL
H.	NULL
,	NULL
A.	NULL
O'Garra	NULL
,	NULL
M.	NULL
Bigler	NULL
,	NULL
M.	NULL
Rouleau	NULL
,	NULL
S.	NULL
Antonenko	NULL
,	NULL
J.	NULL
E.	NULL
de	NULL
Vries	NULL
,	NULL
and	NULL
M.	NULL
G.	NULL
Roncarolo	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
CD4*	NULL
T-cell	NULL
subset	NULL
inhibits	NULL
antigen-specific	NULL
T-cell	NULL
responses	NULL
and	NULL
prevents	NULL
colitis	NULL
.	NULL

Nature	NULL
389:737	NULL
.	NULL

Saoudi	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Kubn	NULL
,	NULL
K.	NULL
Huygen	NULL
,	NULL
Y.	NULL
de	NULL
Kozak	NULL
,	NULL
T.	NULL
Velu	NULL
,	NULL
M.	NULL
Goldman	NULL
,	NULL
P.	NULL
Druct	NULL
,	NULL
and	NULL
B.	NULL
Bellon	NULL
.	NULL

1993	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
THI1-TH2	NULL
balance	NULL
in	NULL
the	NULL
development	NULL
of	NULL
autoimmunity	NULL
in	NULL
rats	NULL
.	NULL

Transplant	NULL
.	NULL

Proc	NULL
.	NULL

25:2824	NULL
.	NULL

De	NULL
Carli	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
M.	NULL
D'Elios	NULL
,	NULL
G.	NULL
Zancuoghi	NULL
,	NULL
S.	NULL
Romagnani	NULL
,	NULL
and	NULL
G.	NULL
Del	NULL
Prete	NULL
.	NULL

1994	NULL
.	NULL

Human	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
:	NULL
functional	NULL
properties	NULL
,	NULL
regulation	NULL
of	NULL
development	NULL
and	NULL
role	NULL
in	NULL
autoimmunity	NULL
.	NULL

Autoimmunity	NULL
18:301	NULL
.	NULL

Romagnani	NULL
,	NULL
S.	NULL
1996	NULL
.	NULL

Th1	NULL
and	NULL
Th2	NULL
in	NULL
human	NULL
diseases	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Immuno-pathol	NULL
.	NULL

80:225	NULL
.	NULL

Saoudi	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Kubn	NULL
,	NULL
K.	NULL
Huygen	NULL
,	NULL
Y.	NULL
de	NULL
Kozak	NULL
,	NULL
T.	NULL
Velu	NULL
,	NULL
M.	NULL
Goldman	NULL
,	NULL
P.	NULL
Druct	NULL
,	NULL
and	NULL
B.	NULL
Bellon	NULL
.	NULL

1993	NULL
.	NULL

TH2	NULL
activated	NULL
cells	NULL
prevent	NULL
experimental	NULL
autoimmune	NULL
uveo-retinitis	NULL
,	NULL
a	NULL
TH1-dependent	NULL
autoimmune	NULL
disease	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

23:3096.	NULL
van	NULL
der	NULL
Veen	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Stohlman	NULL
.	NULL

1993	NULL
.	NULL

Encephalitogenic	NULL
Th1	NULL
cells	NULL
are	NULL
inhibited	NULL
by	NULL
Th2	NULL
cells	NULL
with	NULL
related	NULL
peptide	NULL
specificity	NULL
:	NULL
relative	NULL
roles	NULL
of	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-4	NULL
and	NULL
IL-10	NULL
.	NULL

J.	NULL
Neuwroimmunol	NULL
.	NULL

48:213	NULL
.	NULL

Liblau	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
S.	NULL
M.	NULL
Singer	NULL
,	NULL
and	NULL
H.	NULL
O.	NULL
McDevitt	NULL
.	NULL

1995	NULL
.	NULL

Th1	NULL
and	NULL
Th2	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
organ-specific	NULL
autoimmune	NULL
diseases	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
16	NULL
:	NULL
34	NULL
.	NULL

Simon	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
E.	NULL
Seipelt	NULL
,	NULL
and	NULL
J.	NULL
Sieper	NULL
.	NULL

1994	NULL
.	NULL

Divergent	NULL
T-cell	NULL
cytokine	NULL
patterns	NULL
in	NULL
inflammatory	NULL
arthritis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:8562	NULL
.	NULL

Schulze-Koops	NULL
,	NULL
H.	NULL
,	NULL
P.	NULL
E.	NULL
Lipsky	NULL
,	NULL
A.	NULL
F.	NULL
Kavanaugh	NULL
,	NULL
and	NULL
L.	NULL
S.	NULL
Davis	NULL
.	NULL

1995	NULL
.	NULL

Elevated	NULL
Th1-	NULL
or	NULL
ThO-like	NULL
cytokine	NULL
mRNA	NULL
in	NULL
peripheral	NULL
circulation	NULL
of	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
:	NULL
modulation	NULL
by	NULL
treatment	NULL
with	NULL
anti-ICAM-1	NULL
correlates	NULL
with	NULL
clinical	NULL
benefit	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:5029	NULL
.	NULL

Miltenburg	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
J.	NULL
M.	NULL
van	NULL
Laar	NULL
,	NULL
R.	NULL
de	NULL
Kuiper	NULL
,	NULL
M.	NULL
R.	NULL
Daha	NULL
,	NULL
and	NULL
F.	NULL
C.	NULL
Breedveld	NULL
.	NULL

1992	NULL
.	NULL

T	NULL
cells	NULL
cloned	NULL
from	NULL
human	NULL
rheumatoid	NULL
synovial	NULL
membrane	NULL
functionally	NULL
represent	NULL
the	NULL
Th1	NULL
subset	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

35:603	NULL
.	NULL

Quayle	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
P.	NULL
Chomarat	NULL
,	NULL
P.	NULL
Miossec	NULL
,	NULL
J.	NULL
Kjeldsen-Kragh	NULL
,	NULL
O.	NULL
Forre	NULL
,	NULL
and	NULL
J	NULL
.	NULL

B.	NULL
Natvig	NULL
.	NULL

1993	NULL
.	NULL

Rheumatoid	NULL
inflammatory	NULL
T-cell	NULL
clones	NULL
express	NULL
mostly	NULL
Th1	NULL
but	NULL
also	NULL
Th2	NULL
and	NULL
mixed	NULL
(	NULL
ThO	NULL
)	NULL
cytokine	NULL
patterns	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

38:75	NULL
.	NULL

Dolhain	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
A.	NULL
N.	NULL
van	NULL
der	NULL
Heiden	NULL
,	NULL
N.	NULL
T.	NULL
ter	NULL
Haar	NULL
,	NULL
F.	NULL
C.	NULL
Breedveld	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Miltenburg	NULL
.	NULL

1996	NULL
.	NULL

Shift	NULL
toward	NULL
T	NULL
lymphocytes	NULL
with	NULL
a	NULL
T	NULL
helper	NULL
1	NULL
cytokine-secretion	NULL
profile	NULL
in	NULL
the	NULL
joints	NULL
of	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

39:1961	NULL
.	NULL

Kusaba	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Honda	NULL
,	NULL
T.	NULL
Fukuda	NULL
,	NULL
and	NULL
K.	NULL
Oizumi	NULL
.	NULL

1998	NULL
.	NULL

Analysis	NULL
of	NULL
type	NULL
1	NULL
and	NULL
type	NULL
2	NULL
T	NULL
cells	NULL
in	NULL
synovial	NULL
fluid	NULL
and	NULL
peripheral	NULL
blood	NULL
of	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

J.	NULL
Rheumatol	NULL
.	NULL

25:1466	NULL
.	NULL

Morita	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Yamamura	NULL
,	NULL
M.	NULL
Kawashima	NULL
,	NULL
S.	NULL
Harada	NULL
,	NULL
K.	NULL
Tsuji	NULL
,	NULL
K.	NULL
Shibuya	NULL
,	NULL
K.	NULL
Maruyama	NULL
,	NULL
and	NULL
H.	NULL
Makino	NULL
.	NULL

1998	NULL
.	NULL

Flow	NULL
cytometric	NULL
single-cell	NULL
analysis	NULL
of	NULL
T	NULL
CELL	NULL
DIFFERENTIATION	NULL
IN	NULL
RHEUMATOID	NULL
ARTHRITIS	NULL
23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48.	NULL
cytokine	NULL
production	NULL
by	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
synovial	NULL
tissue	NULL
and	NULL
peripheral	NULL
blood	NULL
from	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

41:1669	NULL
.	NULL

Swain	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
A.	NULL
D.	NULL
Weinberg	NULL
,	NULL
M.	NULL
English	NULL
,	NULL
and	NULL
G.	NULL
Huston	NULL
.	NULL

1990	NULL
.	NULL

IL-4	NULL
directs	NULL
the	NULL
development	NULL
of	NULL
Th2-like	NULL
helper	NULL
effectors	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:3796	NULL
.	NULL

Le	NULL
Gros	NULL
,	NULL
G.	NULL
,	NULL
S.	NULL
Z.	NULL
Ben-Sasson	NULL
,	NULL
R.	NULL
Seder	NULL
,	NULL
F.	NULL
D.	NULL
Finkelman	NULL
,	NULL
and	NULL
W.	NULL
E.	NULL
Paul	NULL
.	NULL

1990	NULL
.	NULL

Generation	NULL
of	NULL
interleukin	NULL
4	NULL
(	NULL
IL-4	NULL
)	NULL
-producing	NULL
cells	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
:	NULL
IL-2	NULL
and	NULL
IL-4	NULL
are	NULL
required	NULL
for	NULL
in	NULL
vitro	NULL
generation	NULL
of	NULL
IL-4-	NULL
producing	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:921	NULL
.	NULL

Seder	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
W.	NULL
E.	NULL
Paul	NULL
,	NULL
M.	NULL
M.	NULL
Davis	NULL
,	NULL
and	NULL
B.	NULL
Fazekas	NULL
de	NULL
St.Groth	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
interleukin	NULL
4	NULL
during	NULL
in	NULL
vitro	NULL
priming	NULL
determines	NULL
the	NULL
lymphokine-producing	NULL
potential	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
T	NULL
cell	NULL
receptor	NULL
transgenic	NULL
mice	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:1091	NULL
.	NULL

Hsich	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Heimberger	NULL
,	NULL
J.	NULL
S.	NULL
Gold	NULL
,	NULL
A.	NULL
O'Garra	NULL
,	NULL
and	NULL
K.	NULL
M.	NULL
Murphy	NULL
.	NULL

1992	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
T	NULL
helper	NULL
phenotype	NULL
development	NULL
by	NULL
interleukins	NULL
4	NULL
and	NULL
10	NULL
in	NULL
an	NULL
eB	NULL
T-cell-receptor	NULL
transgenic	NULL
system	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
;	NULL
6065	NULL
.	NULL

Maggi	NULL
,	NULL
E.	NULL
,	NULL
P.	NULL
Parronchi	NULL
,	NULL
R.	NULL
Manetti	NULL
,	NULL
C.	NULL
Simonelli	NULL
,	NULL
M.	NULL
P.	NULL
Piccinni	NULL
,	NULL
F.	NULL
S.	NULL
Rugiu	NULL
,	NULL
M.	NULL
De	NULL
Carli	NULL
,	NULL
M.	NULL
Ricci	NULL
,	NULL
and	NULL
S.	NULL
Romagnani	NULL
.	NULL

1992	NULL
.	NULL

Reciprocal	NULL
regulatory	NULL
effects	NULL
of	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
on	NULL
the	NULL
in	NULL
vitro	NULL
development	NULL
of	NULL
human	NULL
Th1	NULL
and	NULL
Th2	NULL
clones	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

148:2142	NULL
.	NULL

Perez	NULL
,	NULL
V.	NULL
L.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Lederer	NULL
,	NULL
A.	NULL
H.	NULL
Lichtman	NULL
,	NULL
and	NULL
A.	NULL
K.	NULL
Abbas	NULL
.	NULL

1995	NULL
.	NULL

Stability	NULL
of	NULL
Th1	NULL
and	NULL
Th2	NULL
populations	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

7:869	NULL
.	NULL

Seder	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
R.	NULL
Gazzinelli	NULL
,	NULL
A.	NULL
Sher	NULL
,	NULL
and	NULL
W.	NULL
E.	NULL
Paul	NULL
.	NULL

1993	NULL
.	NULL

Interleukin	NULL
12	NULL
acts	NULL
directly	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
to	NULL
enhance	NULL
priming	NULL
for	NULL
interferon	NULL
y	NULL
production	NULL
and	NULL
diminishes	NULL
interleukin	NULL
4	NULL
inhibition	NULL
of	NULL
such	NULL
priming	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:10188	NULL
.	NULL

Hsich	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
S.	NULL
E.	NULL
Macatonia	NULL
,	NULL
C.	NULL
S.	NULL
Tripp	NULL
,	NULL
S.	NULL
F.	NULL
Wolf	NULL
,	NULL
A.	NULL
O'Garra	NULL
,	NULL
and	NULL
K.	NULL
M.	NULL
Murphy	NULL
.	NULL

1993	NULL
.	NULL

Development	NULL
of	NULL
THI	NULL
CD4*	NULL
T	NULL
cells	NULL
through	NULL
IL-12	NULL
produced	NULL
by	NULL
Listeria-induced	NULL
macrophages	NULL
.	NULL

Science	NULL
260:547	NULL
.	NULL

Constant	NULL
,	NULL
S.	NULL
,	NULL
C.	NULL
Pfeiffer	NULL
,	NULL
A.	NULL
Woodard	NULL
,	NULL
T.	NULL
Pasqualini	NULL
,	NULL
and	NULL
K.	NULL
Bottomly	NULL
.	NULL

1995	NULL
.	NULL

Extent	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
ligation	NULL
can	NULL
determine	NULL
the	NULL
functional	NULL
differentiation	NULL
of	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:1591	NULL
.	NULL

Hosken	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
K.	NULL
Shibuya	NULL
,	NULL
A.	NULL
W.	NULL
Heath	NULL
,	NULL
K.	NULL
M.	NULL
Murphy	NULL
,	NULL
and	NULL
A.	NULL
O'Garra	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
antigen	NULL
dose	NULL
on	NULL
CD4	NULL
*	NULL
T	NULL
helper	NULL
cell	NULL
phenotype	NULL
development	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
receptor-af-transgenic	NULL
model	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:1579	NULL
.	NULL

Kuchroo	NULL
,	NULL
V.	NULL
K.	NULL
,	NULL
M.	NULL
P.	NULL
Das	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Brown	NULL
,	NULL
A.	NULL
M.	NULL
Ranger	NULL
,	NULL
S.	NULL
S.	NULL
Zamvil	NULL
,	NULL
R.	NULL
A.	NULL
Sobel	NULL
,	NULL
H.	NULL
L.	NULL
Weiner	NULL
,	NULL
N.	NULL
Nabavi	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1995	NULL
.	NULL

B7-1	NULL
and	NULL
B7-2	NULL
costimulatory	NULL
molecules	NULL
activate	NULL
differentially	NULL
the	NULL
Th1/Th2	NULL
developmental	NULL
pathways	NULL
:	NULL
application	NULL
to	NULL
autoimmune	NULL
disease	NULL
therapy	NULL
.	NULL

Cell	NULL
80:707	NULL
.	NULL

King	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
R.	NULL
J.	NULL
Stupi	NULL
,	NULL
N.	NULL
Craighead	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
and	NULL
G.	NULL
Thyphronitis	NULL
.	NULL

1995	NULL
.	NULL

CD28	NULL
activation	NULL
promotes	NULL
Th2	NULL
subset	NULL
differentiation	NULL
by	NULL
human	NULL
CD4	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25:587	NULL
.	NULL

Rulifson	NULL
,	NULL
I.	NULL
C.	NULL
,	NULL
A.	NULL
I.	NULL
Sperling	NULL
,	NULL
P.	NULL
E.	NULL
Fields	NULL
,	NULL
F.	NULL
W.	NULL
Fitch	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
.	NULL

1997	NULL
.	NULL

CD28	NULL
costimulation	NULL
promotes	NULL
the	NULL
production	NULL
of	NULL
Th2	NULL
cytokines	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158	NULL
:	NULL
658	NULL
.	NULL

Palmer	NULL
,	NULL
E.	NULL
M.	NULL
and	NULL
G.	NULL
A	NULL
.	NULL

Van	NULL
Seventer	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
T	NULL
helper	NULL
cell	NULL
differentiation	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
combined	NULL
action	NULL
of	NULL
cytokines	NULL
and	NULL
accessory	NULL
cell-dependent	NULL
costimulatory	NULL
signals	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:2654	NULL
.	NULL

Schulze-Koops	NULL
,	NULL
H.	NULL
,	NULL
P.	NULL
E.	NULL
Lipsky	NULL
,	NULL
and	NULL
L.	NULL
S.	NULL
Davis	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
memory	NULL
T	NULL
cell	NULL
differentiation	NULL
into	NULL
Th2-like	NULL
effector	NULL
cells	NULL
is	NULL
dependent	NULL
on	NULL
IL-4	NULL
and	NULL
CD28	NULL
and	NULL
inhibited	NULL
by	NULL
TCR	NULL
ligation	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28:2517	NULL
.	NULL

Kohem	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
R.	NULL
I.	NULL
Brezinschek	NULL
,	NULL
H.	NULL
Wisbey	NULL
,	NULL
C.	NULL
Tortorella	NULL
,	NULL
P.	NULL
E.	NULL
Lipsky	NULL
,	NULL
and	NULL
N.	NULL
Oppenheimer-Marks	NULL
.	NULL

1996	NULL
.	NULL

Enrichment	NULL
of	NULL
differentiated	NULL
CD45RB	NULL
``	NULL
,	NULL
CD27~	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
,	NULL
synovial	NULL
fluid	NULL
,	NULL
and	NULL
synovial	NULL
tissue	NULL
of	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

39:844	NULL
.	NULL

Davis	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
N.	NULL
Oppenheimer-Marks	NULL
,	NULL
H.	NULL
Schulze-Koops	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1998	NULL
.	NULL

Th1/Th2	NULL
cytokine	NULL
balance	NULL
in	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

41:1896	NULL
.	NULL

Sornasse	NULL
,	NULL
T.	NULL
,	NULL
P.	NULL
V.	NULL
Larenas	NULL
,	NULL
K.	NULL
A.	NULL
Davis	NULL
,	NULL
J.	NULL
E.	NULL
de	NULL
Vries	NULL
,	NULL
and	NULL
H.	NULL
Yssel	NULL
.	NULL

1996	NULL
.	NULL

Differentiation	NULL
and	NULL
stability	NULL
of	NULL
T	NULL
helper	NULL
1	NULL
and	NULL
2	NULL
cells	NULL
derived	NULL
from	NULL
naive	NULL
human	NULL
neonatal	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
analyzed	NULL
at	NULL
the	NULL
single-cell	NULL
level	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:473	NULL
.	NULL

Arnett	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
S.	NULL
M.	NULL
Edworthy	NULL
,	NULL
D.	NULL
A.	NULL
Bloch	NULL
,	NULL
D.	NULL
J.	NULL
McShane	NULL
,	NULL
J.	NULL
F.	NULL
Fries	NULL
,	NULL
N.	NULL
S.	NULL
Cooper	NULL
,	NULL
L.	NULL
A.	NULL
Healey	NULL
,	NULL
S.	NULL
R.	NULL
Kaplan	NULL
,	NULL
M.	NULL
H.	NULL
Liang	NULL
,	NULL
H.	NULL
S.	NULL
Luthra	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
American	NULL
Rheumatism	NULL
Association	NULL
1987	NULL
revised	NULL
criteria	NULL
for	NULL
the	NULL
classification	NULL
of	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

31:315	NULL
.	NULL

Rosenberg	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1979	NULL
.	NULL

Monocyte	NULL
dependence	NULL
of	NULL
pokeweed	NULL
mitogen-induced	NULL
differentiation	NULL
of	NULL
immunoglobulin-secreting	NULL
cells	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

122:926	NULL
.	NULL

Maurice	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
A.	NULL
C.	NULL
Lankester	NULL
,	NULL
A.	NULL
C.	NULL
Bezemer	NULL
,	NULL
M.	NULL
F.	NULL
Geertsma	NULL
,	NULL
P.	NULL
P.	NULL
Tak	NULL
,	NULL
F.	NULL
C.	NULL
Breedveld	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

Van	NULL
Lier	NULL
,	NULL
and	NULL
C.	NULL
L.	NULL
Verweij	NULL
.	NULL

1997	NULL
.	NULL

Defective	NULL
TCR-mediated	NULL
signaling	NULL
in	NULL
synovial	NULL
T	NULL
cells	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159	NULL
;	NULL
2973.	NULL
.	NULL

Shimoda	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
van	NULL
Deursen	NULL
,	NULL
M.	NULL
Y.	NULL
Sangster	NULL
,	NULL
S.	NULL
R.	NULL
Sarawar	NULL
,	NULL
R.	NULL
T.	NULL
Carson	NULL
,	NULL
R.	NULL
A.	NULL
Tripp	NULL
,	NULL
C.	NULL
Chu	NULL
,	NULL
F.	NULL
W.	NULL
Quelle	NULL
,	NULL
T.	NULL
Nosaka	NULL
,	NULL
D.	NULL
A.	NULL
Vignali	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

Lack	NULL
of	NULL
IL-4-induced	NULL
Th2	NULL
response	NULL
and	NULL
IgE	NULL
class	NULL
switching	NULL
in	NULL
mice	NULL
with	NULL
disrupted	NULL
Stat6	NULL
gene	NULL
.	NULL

Nature	NULL
380:630	NULL
.	NULL

Takeda	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Tanaka	NULL
,	NULL
W.	NULL
Shi	NULL
,	NULL
M.	NULL
Matsumoto	NULL
,	NULL
M.	NULL
Minami	NULL
,	NULL
S.	NULL
Kashiwamura	NULL
,	NULL
K.	NULL
Nakanishi	NULL
,	NULL
N.	NULL
Yoshida	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
and	NULL
S.	NULL
Akira	NULL
.	NULL

1996	NULL
.	NULL

Essential	NULL
role	NULL
of	NULL
Stat6	NULL
in	NULL
IL-4	NULL
signalling	NULL
.	NULL

Nature	NULL
380:627	NULL
.	NULL

Kaplan	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
U.	NULL
Schindler	NULL
,	NULL
S.	NULL
T.	NULL
Smiley	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Grusby	NULL
.	NULL

1996	NULL
.	NULL

Stat6	NULL
is	NULL
required	NULL
for	NULL
mediating	NULL
responses	NULL
to	NULL
IL-4	NULL
and	NULL
for	NULL
development	NULL
of	NULL
Th2	NULL
cells	NULL
.	NULL

Immunity	NULL
4:313	NULL
.	NULL

Panayi	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
J.	NULL
S.	NULL
Lanchbury	NULL
,	NULL
and	NULL
G.	NULL
H.	NULL
Kingsley	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
in	NULL
initiating	NULL
and	NULL
maintaining	NULL
the	NULL
chronic	NULL
synovitis	NULL
of	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

35:729	NULL
.	NULL

Lipsky	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
L.	NULL
S.	NULL
Davis	NULL
,	NULL
J.	NULL
J.	NULL
Cush	NULL
,	NULL
and	NULL
N.	NULL
Oppenheimer-Marks	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
role	NULL
of	NULL
cytokines	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Springer	NULL
Semin	NULL
.	NULL

Immu-nopathol	NULL
.	NULL

11:123	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

King	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
J.	NULL
Xianli	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
R.	NULL
Abe	NULL
,	NULL
and	NULL
K.	NULL
P.	NULL
Lee	NULL
.	NULL

1996	NULL
.	NULL

CD28-deficient	NULL
mice	NULL
generate	NULL
an	NULL
impaired	NULL
Th2	NULL
response	NULL
to	NULL
Schistosoma	NULL
mansoni	NULL
infection	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

26:2448	NULL
.	NULL

Keane-Myers	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
C.	NULL
Gause	NULL
,	NULL
P.	NULL
S.	NULL
Linsley	NULL
,	NULL
S.	NULL
J.	NULL
Chen	NULL
,	NULL
and	NULL
M.	NULL
Wills-Karp	NULL
.	NULL

1997	NULL
.	NULL

B7-CD28/CTLA-4	NULL
costimulatory	NULL
pathways	NULL
are	NULL
required	NULL
for	NULL
the	NULL
development	NULL
of	NULL
T	NULL
helper	NULL
cell	NULL
2-mediated	NULL
allergic	NULL
airway	NULL
responses	NULL
to	NULL
inhaled	NULL
antigens	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:2042	NULL
.	NULL

Rudd	NULL
,	NULL
C.	NULL
E.	NULL
1996	NULL
.	NULL

Upstream-downstream	NULL
:	NULL
CD28	NULL
cosignaling	NULL
pathways	NULL
and	NULL
T	NULL
cell	NULL
function	NULL
.	NULL

Immunity	NULL
4:527	NULL
.	NULL

Ward	NULL
,	NULL
S.	NULL
G.	NULL
1996	NULL
.	NULL

CD28	NULL
:	NULL
a	NULL
signalling	NULL
perspective	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

318:361	NULL
.	NULL

Sicfken	NULL
,	NULL
R.	NULL
,	NULL
S.	NULL
Klein-Hessling	NULL
,	NULL
E.	NULL
Serfling	NULL
,	NULL
R.	NULL
Kurrle	NULL
,	NULL
and	NULL
R.	NULL
Schwinzer	NULL
.	NULL

1998	NULL
.	NULL

A	NULL
CD28-associated	NULL
signaling	NULL
pathway	NULL
leading	NULL
to	NULL
cytokine	NULL
gene	NULL
transcription	NULL
and	NULL
T	NULL
cell	NULL
proliferation	NULL
without	NULL
TCR	NULL
engagement	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:1645	NULL
.	NULL

Verwilghen	NULL
,	NULL
J.	NULL
,	NULL
V.	NULL
Corrigall	NULL
,	NULL
R.	NULL
M.	NULL
Pope	NULL
,	NULL
R.	NULL
Rodrigues	NULL
,	NULL
and	NULL
G.	NULL
S.	NULL
Panayi	NULL
.	NULL

1993	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
CDS	NULL
and	NULL
CD28	NULL
in	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Immunology	NULL
80:96	NULL
.	NULL

Sfikakis	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
A.	NULL
Zografou	NULL
,	NULL
V.	NULL
Viglis	NULL
,	NULL
A.	NULL
Iniotaki-Theodoraki	NULL
,	NULL
I.	NULL
Piskontaki	NULL
,	NULL
G.	NULL
C.	NULL
Tsokos	NULL
,	NULL
P.	NULL
Sfikakis	NULL
,	NULL
and	NULL
H.	NULL
Choremi-Papadopoulou	NULL
.	NULL

1995	NULL
.	NULL

CD28	NULL
expression	NULL
on	NULL
T	NULL
cell	NULL
subsets	NULL
in	NULL
vivo	NULL
and	NULL
CD28-mediated	NULL
T	NULL
cell	NULL
response	NULL
in	NULL
vitro	NULL
in	NULL
patients	NULL
with	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

38:649	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

499	NULL
Maurice	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
E.	NULL
A.	NULL
van	NULL
der	NULL
Voort	NULL
,	NULL
A.	NULL
Leow	NULL
,	NULL
N.	NULL
Levarht	NULL
,	NULL
F.	NULL
C.	NULL
Breedveld	NULL
,	NULL
and	NULL
C.	NULL
L.	NULL
Verweij	NULL
.	NULL

1998	NULL
.	NULL

CD28	NULL
co-stimulation	NULL
is	NULL
intact	NULL
and	NULL
contributes	NULL
to	NULL
prolonged	NULL
ex	NULL
vivo	NULL
survival	NULL
of	NULL
hyporesponsive	NULL
synovial	NULL
fluid	NULL
T	NULL
cells	NULL
in	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28:1554	NULL
.	NULL

Davis	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
H.	NULL
Schulze-Koops	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Lipsky	NULL
.	NULL

1997	NULL
.	NULL

Rheumatoid	NULL
synovial	NULL
memory	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
primed	NULL
in	NULL
vivo	NULL
to	NULL
be	NULL
interferon-y	NULL
producers	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

40:8532	NULL
.	NULL

Thile	NULL
,	NULL
J.	NULL
N.	NULL
1995	NULL
.	NULL

Cytokine	NULL
receptor	NULL
signalling	NULL
.	NULL

Nature	NULL
377:591	NULL
.	NULL

Hou	NULL
,	NULL
J.	NULL
,	NULL
U.	NULL
Schindler	NULL
,	NULL
W.	NULL
J.	NULL
Henzel	NULL
,	NULL
T.	NULL
C.	NULL
Ho	NULL
,	NULL
M.	NULL
Brasseur	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
interleukin-4-induced	NULL
transcription	NULL
factor	NULL
:	NULL
IL-4	NULL
Stat	NULL
.	NULL

Science	NULL
265:1701	NULL
.	NULL

Huang	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
W.	NULL
E.	NULL
Paul	NULL
.	NULL

1998	NULL
.	NULL

Impaired	NULL
interleukin	NULL
4	NULL
signaling	NULL
in	NULL
T	NULL
helper	NULL
type	NULL
1	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:1305	NULL
.	NULL

Klimiuk	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
J.	NULL
J.	NULL
Goronzy	NULL
,	NULL
J.	NULL
Bjornsson	NULL
,	NULL
R.	NULL
D.	NULL
Beckenbaugh	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Weyand	NULL
.	NULL

1997	NULL
.	NULL

Tissue	NULL
cytokine	NULL
patterns	NULL
distinguish	NULL
variants	NULL
of	NULL
rheumatoid	NULL
synovitis	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

151:1311	NULL
.	NULL

Stichl	NULL
,	NULL
P.	NULL
,	NULL
W.	NULL
Keitel	NULL
,	NULL
R.	NULL
Becker	NULL
,	NULL
and	NULL
H.	NULL
Kuhn	NULL
.	NULL

1998	NULL
.	NULL

Differential	NULL
synovial	NULL
his-tology	NULL
for	NULL
the	NULL
characterization	NULL
of	NULL
a	NULL
possible	NULL
heterogeneity	NULL
and	NULL
prognosis	NULL
of	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

Z.	NULL
Rheumatol	NULL
.	NULL

57:546	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

